Document:

EX-10.13

 Exhibit 10.13 
 INDEMNIFICATION AGREEMENT 
 This Agreement,
made and entered into this      day of              (“Agreement”), by and between Concert Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), and
[                                        ] (the
[“Officer] [“Director”]; collectively with such [Officer’s] [Director’s] Affiliated Persons (as defined in Section 19(a) hereof), “Indemnitee” or “Indemnitees”): 

WHEREAS, it is reasonable, prudent and necessary for the Company to obligate itself to indemnify, and to advance expenses on behalf of,
its directors and executive officers to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and 

WHEREAS, Indemnitee is willing to serve, continue to serve the Company as a director and/or executive officer and to take on additional
service for or on its behalf on the condition that he be so indemnified; 
 NOW, THEREFORE, in consideration of the premises and
the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows: 
  

	1.	Services by Indemnitee. Indemnitee agrees to serve as a director and/or executive officer of the Company. Indemnitee may at any time and for any reason resign
from such position (subject to any other contractual obligation or any obligation imposed by operation of law). 

  

	2.	Indemnification - General. The Company shall indemnify, and advance Expenses (as hereinafter defined) to, Indemnitee (a) as provided in this Agreement and
(b) (subject to the provisions of this Agreement) to the fullest extent permitted by applicable law in effect on the date hereof and as amended from time to time. The rights of Indemnitee provided under the preceding sentence shall include, but
shall not be limited to, the rights set forth in the other Sections of this Agreement. 

  

	3.	Proceedings Other Than Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this
Section 3 if, by reason of Indemnitee’s Corporate Status (as hereinafter defined), Indemnitee is, or is threatened to be made, a party to or a participant in any threatened, pending or completed Proceeding (as hereinafter defined), other
than a Proceeding by or in the right of the Company. Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, penalties, fines and amounts paid in settlement (including all interest, assessments and other
charges paid or payable in connection with or in respect of such Expenses, judgments, penalties, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on behalf of Indemnitee in connection with such Proceeding or
any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, with respect to any criminal Proceeding, had no reasonable cause
to believe Indemnitee’s conduct was unlawful. 

  

	4.	 Proceedings by or in the Right of the Company. Indemnitee shall be entitled to the rights of indemnification provided in this Section 4 if,
by reason of Indemnitee’s Corporate 

	 	
Status, Indemnitee is, or is threatened to be made, a party to or a participant in any threatened, pending or completed Proceeding brought by or in the right of the Company to procure a judgment
in its favor. Pursuant to this Section, Indemnitee shall be indemnified against all Expenses (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses) actually and reasonably incurred
by Indemnitee or on behalf of Indemnitee in connection with such Proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided,
however, that indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company if and only to the extent that the Court
of Chancery of the State of Delaware, or the court in which such Proceeding shall have been brought or is pending, shall determine that such indemnification may be made. 

 

	5.	Partial Indemnification. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee’s Corporate
Status, a party to (or a participant in) and is successful, on the merits or otherwise, in defense of any Proceeding, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on behalf of Indemnitee in
connection therewith. If Indemnitee is not wholly successful in defense of such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify
Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on behalf of Indemnitee in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of
any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. If Indemnitee is entitled under any provision of this agreement to indemnification
by the Company for some or a portion of the Expenses, judgments, penalties, fines and amounts paid in settlement (including all interest, assessments and Other charges paid or payable in connection with or in respect of such Expenses, judgments,
penalties, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on behalf of Indemnitee in connection with such Proceeding or any claim, issue or matter therein, but not, however, for the total amount thereof, the
Company shall nevertheless indemnify Indemnitee for the portion to which Indemnitee is entitled. 

  

	6.	Indemnification for Additional Expenses. 

  

	 	a.	The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within five (5) business days of such request) advance
such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for (i) indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement or by-law of the
Company now or hereafter in effect; or (ii) recovery under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such
indemnification, advance expense payment or insurance recovery, as the case may be. 

  

	 	b.	Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee’s Corporate Status, a witness in any Proceeding to
which Indemnitee is not a party, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on behalf of Indemnitee in connection therewith. 

	7.	Advancement of Expenses. The Company shall advance all reasonable Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding within five
(5) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall
reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by an undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not
entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the obligation of the Company to advance Expenses pursuant to this Section 7 shall be subject to the condition that, if, when and to the extent that the Company
determines that Indemnitee would not be permitted to be indemnified under applicable law, the Company shall be entitled to be reimbursed, within thirty (30) days of such determination, by Indemnitee (who hereby agrees to reimburse the Company)
for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences legal proceedings in a court of competent jurisdiction to secure a determination that Indemnitee should be indemnified
under applicable law, any determination made by the Company that Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and Indemnitee shall not be required to reimburse the Company for any advance of Expenses
until a final judicial determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed). 

  

	8.	Procedure for Determination of Entitlement to Indemnification. 

  

	 	a.	To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and
information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for
indemnification, advise the Board in writing that Indemnitee has requested indemnification. 

  

	 	b.	 Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 8(a) hereof, a determination, if required by
applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control (as hereinafter defined) shall have occurred, by Independent Counsel (as hereinafter defined) in a written
opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee; or (ii) if a Change of Control shall not have occurred, (A) by a majority vote of the Disinterested Directors (as hereinafter defined), even though less
than a quorum of the Board, or (B) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or
(C) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within seven (7) days after such determination. The
Company and Indemnitee shall each cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to

	 	
such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to
Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne
by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification), and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 

 

	 	c.	In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 8(b) hereof, the Independent Counsel
shall be selected as provided in this Section 8(c). If a Change of Control shall not have occurred, the Independent Counsel shall be selected by the Board of Directors, and the Company shall give written notice to Indemnitee advising him of the
identity of the Independent Counsel so selected. If a Change of Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board of Directors, in which
event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten
(10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted
only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 19 of this Agreement, and the objection shall set forth with particularity the factual basis of
such assertion. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without
merit. If, within twenty (20) days after submission by Indemnitee of a written request for indemnification pursuant to Section 8(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or
Indemnitee may petition the Court of Chancery of the State of Delaware for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as
Independent Counsel of a person selected by the Court or by such other person as the Court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under
Section 8(b) hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 8(b) hereof, and the Company shall pay all
reasonable fees and expenses incident to the procedures of this Section 8(c), regardless of the manner in which such Independent Counsel was selected or appointed, and if such Independent Counsel was selected or appointed by Indemnitee or the
Court, shall provide such Independent Counsel with such retainer as may requested by such counsel. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 10(a)(iii) of this Agreement, Independent Counsel shall
be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

  

	 	d.	The Company shall not be required to obtain the consent of Indemnitee to the settlement of any Proceeding which the Company has undertaken to defend if the Company
assumes full and sole responsibility for such settlement and the settlement grants Indemnitee a complete and unqualified release in respect of the potential liability. The Company shall not be liable for any amount paid by Indemnitee in settlement
of any Proceeding that is not defended by the Company, unless the Company has consented to such settlement, which consent shall not be unreasonably withheld. 

	9.	Presumptions and Effect of Certain Proceedings. 

  

	 	a.	In making a determination with respect to entitlement to indemnification or the advancement of expenses hereunder, the person or persons or entity making such
determination shall presume that Indemnitee is entitled to indemnification or advancement of expenses under this Agreement if Indemnitee has submitted a request for indemnification or the advancement of expenses in accordance with Section 8(a)
of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company
(including its board of directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the
applicable standard of conduct, nor an actual determination by the Company (including its board of directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a
presumption that Indemnitee has not met the applicable standard of conduct. 

  

	 	b.	 If the person, persons or entity empowered or selected under Section 8 of this Agreement to determine whether Indemnitee is entitled to
indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee
shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for
indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or
entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further,
that the foregoing provisions of this Section 9(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 8(b) of this Agreement and if (A) within fifteen
(15) days after receipt by the Company of the request for such determination the Board of Directors has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within
seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such
meeting is held for such purpose 

	 	
within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent
Counsel pursuant to Section 8(b) of this Agreement. 

  

	 	c.	The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or
its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he
reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful. 

 

	 	d.	Reliance as Safe Harbor. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is
based on the records or books of account of the Company or relevant enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Company or relevant enterprise in the course of their duties, or on the
advice of legal counsel for the Company or relevant enterprise or on information or records given in reports made to the Company or relevant enterprise by an independent certified public accountant or by an appraiser or other expert selected with
reasonable care by the Company or relevant enterprise. The provisions of this Section 9(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard
of conduct set forth in this Agreement. 

  

	 	e.	Actions of Others. The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Company or relevant enterprise shall not
be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. 

  

	10.	Remedies of Indemnitee. 

  

	 	a.	In the event that (i) a determination is made pursuant to Section 8 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement,
(ii) advancement of Expenses is not timely made pursuant to Section 7 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 8(b) of this Agreement within ninety
(90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5 or 6 of this Agreement within ten (10) days after receipt by the Company of a written
request therefor, or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Court of
Chancery of the State of Delaware, or any other court of competent jurisdiction, of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a
single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. 

	 	b.	In the event that a determination shall have been made pursuant to Section 8(b) of this Agreement that Indemnitee is not entitled to indemnification, any judicial
proceeding or arbitration commenced pursuant to this Section 10 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. If a
Change of Control shall have occurred, in any judicial proceeding or arbitration commenced pursuant to this Section 10, the Company shall have the burden of proving that Indemnitee is not entitled to indemnification or advancement of Expenses,
as the case may be. 

  

	 	c.	If a determination shall have been made pursuant to Section 8(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by
such determination in any judicial proceeding or arbitration commenced pursuant to this Section 10, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement
not materially misleading in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. 

  

	 	d.	In the event that Indemnitee, pursuant to this Section 10, seeks a judicial adjudication of or an award in arbitration to enforce his rights under, or to recover
damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company against, any and all expenses (of the types described in the definition of Expenses in Section 19 of this
Agreement) actually and reasonably incurred by him in such judicial adjudication or arbitration, but only if he prevails therein. If it shall be determined in said judicial adjudication or arbitration that Indemnitee is entitled to receive part but
not all of the indemnification or advancement of expenses sought, the expenses incurred by Indemnitee in connection with such judicial adjudication or arbitration shall be appropriately prorated. The Company shall indemnify Indemnitee against any
and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action
brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ or officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately
is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. 

  

	 	e.	The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 10 that the procedures and presumptions
of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. 

 

	11.	Non-Exclusivity; Survival of Rights; Insurance; Subrogation. 

  

	 	a.	 The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to
which Indemnitee may at any time be entitled under applicable law, the 

	 	
Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any
provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in Indemnitee’s Corporate Status prior to such amendment, alteration or repeal. To the extent
that a change in the General Corporation Law of the State of Delaware, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Company’s Bylaws and this
Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every
other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise,
shall not prevent the concurrent assertion or employment of any other right or remedy. 

  

	 	b.	To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees or agents of the Company or of
any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms
to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. 

  

	 	c.	In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who
shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit or enforce such rights. 

 

	 	d.	The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise
actually received such payment under any insurance policy, contract, agreement or otherwise. 

  

	 	e.	The Company’s obligation to indemnify or advance expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer,
employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. 

  

	12.	Period of Limitations. No legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against any Indemnitee, such
Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of two (2) years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and
deemed released unless asserted by the timely filing of a legal action within such two (2)-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter
period shall govern. 

	13.	Liability Insurance. To the extent the Company maintains liability insurance applicable to directors, officers, employees, control persons, fiduciaries or other
agents and affiliates, each Indemnitee shall be covered by such policies in such a manner as to provide to the Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if such Indemnitee
is a director, or of the Company’s officers, if such Indemnitee is not a director of the Company but is an officer. 

  

	14.	Duration of Agreement. 

  

	 	a.	This Agreement shall continue until and terminate upon the later of: (i) twenty (20) years after the date that Indemnitee shall have ceased to serve as a
director and/or executive officer of the Company (or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which Indemnitee served at the request of the Company); or (ii) the final termination of
any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 10 of this Agreement relating thereto.

  

	 	b.	This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries) and Indemnitee. Indemnitee specifically acknowledges that
Indemnitee’s employment with the Company (or any of its subsidiaries), if any, is at will, and Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment
contract between Indemnitee and the Company (or any of its subsidiaries), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Company’s Certificate of
Incorporation, Bylaws, and the General Corporation Law of the State of Delaware. The foregoing notwithstanding, this Agreement shall continue in force as provided above after Indemnitee has ceased to serve as a director and/or executive officer of
the Company. 

  

	 	c.	This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his heirs, executors and
administrators. 

  

	15.	Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the
validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not
itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the
intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 

	16.	Exception to Right of Indemnification or Advancement of Expenses. Except as provided in Section 6(a) of this Agreement, Indemnitee shall not be entitled to
indemnification or advancement of Expenses under this Agreement with respect to any Proceeding brought by Indemnitee (other than a Proceeding by Indemnitee to enforce his rights under this Agreement), or any claim therein, unless the bringing of
such Proceeding or making of such claim shall have been approved by the Board of Directors or is otherwise required under Section 145 of the Delaware General Corporation Law, regardless of whether such Indemnitee ultimately is determined to be
entitled to such indemnification, advance expense payment or insurance recovery, as the case may be. 

  

	17.	Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of
which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 

 

	18.	Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to
affect the construction thereof. 

  

	19.	Definitions. For purposes of this Agreement: 

  

	 	a.	“Affiliated Person” of an Indemnitee shall include any director, officer, employee, controlling person (within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act), agent or fiduciary of such Indemnitee, and any stockholder, partner, partnership, corporation, limited liability company, association, joint stock company, trust or joint venture, or similar
entity controlling, controlled by or under common control with the entity or person that such Indemnitee represents in connection with such Indemnitee’s service to the Company. For these purposes, “control” means the possession,
directly or indirectly, of the power to direct management and policies of a person or entity, whether through the ownership of voting securities, contract or otherwise. 

 

	 	b.	“Change in Control” means: 

  

	 	i.	 The acquisition by any person, corporation, partnership, limited liability company or other entity (a “Person”, which term shall include a
group within the meaning of Section 13(d) of the Exchange Act) of ultimate beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act), directly or indirectly of 20% or more of either (i) the then outstanding
shares of common stock of the Company (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the
“Outstanding Company Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change of Control: (i) any such acquisition directly from the Company, except for
acquisition of securities upon conversion of other securities of the Company (ii) any such acquisition by the Company, (iii) any such acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any
corporation controlled by the 

	 	
Company or (iv) any such acquisition by any corporation pursuant to a transaction which complies with clauses (1), (2) and (3) of subsection (iii) of this Section 19(a);
or 

  

	 	ii.	Individuals who, as of the date hereof, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board;
provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election, by the Company’s stockholders, was approved by a vote of at least a majority of the directors then comprising
the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election
contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or 

 

	 	iii.	Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company in one or a series of
transactions (a “Business Combination”), in each case, unless, following such Business Combination, (1) all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company
Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, immediately following such Business Combination more than 50% of, respectively, the outstanding shares of
common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without
limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership,
immediately prior to such Business Combination of the Outstanding Company Common Stock and outstanding Company Voting Securities, as the case may be, (2) no Person (excluding any corporation resulting from such Business Combination or any
employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) ultimately beneficially owns, directly or indirectly, 30% or more of, respectively, the then outstanding shares of common stock of
the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination and (3) at
least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing
for such Business Combination; or 

  

	 	iv.	approval by the stockholders of the Company of a complete liquidation or dissolution of the Company. 

	 	c.	“Corporate Status” describes the status of a person who is or was a director, officer, employee, fiduciary or agent of the Company, or any subsidiary of the
Company, or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person is or was serving at the request of the Company. 

 

	 	d.	“Disinterested Director” means a director of the company who is not and was not a party to the Proceeding in respect of which indemnification is sought by
Indemnitee. 

  

	 	e.	“Effective Date” means                     .

  

	 	f.	“Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses,
duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, and all
other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness, in, or otherwise participating in, a Proceeding.

  

	 	g.	“Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past
five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party, or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an
action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and
damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

  

	 	h.	 “Proceeding” includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation,
inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is, may be
or will be involved as a party or otherwise, by reason of the fact that Indemnitee is or was a director or officer of the Company, or any subsidiary of the Company, by reason of any action taken by him or of any inaction on his part while acting as
director or officer of the Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including,
without limitation, any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, 

	 	
investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal,
administrative or investigative, that arises or may arise, under the Securities Act of 1933, as amended (the “Securities Act”), the Exchange Act or any other federal or state statutory law or regulation, at common law or otherwise, which
relate directly or indirectly (i) to the registration, purchase, sale or ownership of any securities of the Company or(ii) to any fiduciary obligation owed with respect to the Company and its stockholders; in each case whether or not he is
acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement; except one (i) initiated by an Indemnitee pursuant to
Section 10 of this Agreement to enforce his right under this Agreement or (ii) pending on or before the Effective Date. 

  

	20.	Enforcement. 

  

	 	a.	The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to
serve as a director and/or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director and/or officer of the Company. 

 

	 	b.	This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and
understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. 

  

	21.	Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No
waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 

 

	22.	Attorneys’ Fees. In the event that any action is instituted by an Indemnitee under this Agreement, or under any liability insurance policies maintained by
the Company, to enforce or interpret any of the terms hereof or thereof, any Indemnitee shall be entitled to be paid all Expenses incurred by such Indemnitee with respect to such action, regardless of whether such Indemnitee is ultimately successful
in such action, and shall be entitled to the advancement of Expenses with respect to such action, unless, as a part of such action, a court of competent jurisdiction over such action determines that each of the material assertions made by such
Indemnitee as a basis for such action was not made in good faith or was frivolous. 

  

	23.	Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment,
information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any
obligation which it may have to Indemnitee under this Agreement or otherwise. 

	24.	Notices. All notices, requests, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered
by hand and receipted for by the party to whom said notice or other communication shall have been direct, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

  

	 	a.	If to Indemnitee to: 

[INDEMNITEE CONTACT INFORMATION] 
  

	 	b.	If to the Company to: 

 Concert
Pharmaceuticals, Inc. 
 99 Hayden Avenue 
 Lexington, MA 02421 
 or to such other address as may have been furnished to
Indemnitee by the Company or to the Company by Indemnitee, as the case may be. 
  

	25.	Contribution. 

  

	 	a.	To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever,
the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim
relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and
Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i) above but also the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s), as well as any
other relevant equitable considerations. In connection with the registration of the Company’s securities, the relative benefits received by the Company and any Indemnitee shall be deemed to be in the same respective proportions that the net
proceeds from the offering (before deducting expenses) received by the Company and Indemnitee, in each case as set forth in the table on the cover page of the applicable prospectus, bear to the aggregate public offering price of the securities so
offered. The relative fault of the Company and any Indemnitee shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or Indemnitee and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

 

	 	b.	 The Company and each Indemnitee agree that it would not be just and equitable if contribution pursuant to this Section 25 were determined by pro
rata or per 

	 	
capita allocation or by any other method of allocation which does not take account of the equitable considerations referred to in Section 25(a) hereof. In connection with the registration of
the Company’s securities, in no event shall an Indemnitee be required to contribute any amount under this Section 25 in excess of the net proceeds received by such Indemnitee from its sale of securities under such registration statement.
No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent misrepresentation.

  

	26.	Governing Law; Submission to Jurisdiction; Appointment of Agent for Service of Process. This Agreement and the legal relations among the parties shall be
governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 10(a) of this
Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the
“Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or
proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not a resident of the State of Delaware, irrevocably
[                                        ] as its
agent in the State of Delaware for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware,
(iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been
brought in an improper or otherwise inconvenient forum. 

  

	27.	Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. 

[Remainder of Page Intentionally Blank] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year
first above written. 
  

			
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	INDEMNITEE:
	
	  

	Name:	 	
	Title:EX-10.14

 Exhibit 10.14 
 LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY AGREEMENT is made and dated
as of December 22, 2011 and is entered into by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation, and each of its subsidiaries other than Concert Pharmaceuticals Securities Corporation, (hereinafter collectively referred
to as the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”). 
 RECITALS 
 A. Borrower has requested Lender to make available to Borrower a
loan in an aggregate principal amount of up to $20,000,000 (the “Term Loan”); and 
 B. Lender is willing to make the
Term Loan on the terms and conditions set forth in this Agreement. 
 AGREEMENT 

NOW, THEREFORE, Borrower and Lender agree as follows: 
 SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION  

1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings: 

“Account Control Agreement(s)” means any agreement entered into by and among the Lender, Borrower and a third party Bank or
other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Lender a perfected first priority security interest in the subject account or accounts.

 “ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H.

 “Advance(s)” means a Term Advance. 
 “Advance Date” means the funding date of any Advance. 
 “Advance
Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A. 

“Agreement” means this Loan and Security Agreement, as amended from time to time. 

“Assignee” has the meaning given to it in Section 11.13. 

  
 1 

 “Borrower Products” means all products, technical data or technology currently
being developed, manufactured or sold by Borrower or which Borrower intends to sell, manufacture, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, technical
data or technology that have been sold, developed, licensed or distributed by Borrower since its incorporation. 

“Cash” means all cash and liquid funds. 
 “Change in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower in which the holders of
Borrower’s outstanding shares immediately before consummation of such transaction or series of related transactions (together with any affiliates of such holders) do not, immediately after consummation of such transaction or series of related
transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly
owned by such parent), in each case without regard to whether Borrower is the surviving entity, or (ii) sale or issuance by Borrower of new shares of Preferred Stock of Borrower to investors, none of whom are current investors in Borrower (or
their affiliates), representing more than fifty percent (50%) of the voting power of the surviving entity (or the parent of such surviving entity if such surviving entity is wholly owned by such parent); provided, however, none of (a) an
Initial Public Offering or (b) a bona fide equity financing for the purpose of raising capital from institutional investors reasonably acceptable to Lender, shall not constitute a Change in Control. 

“Claims” has the meaning given to it in Section 11.10. 

“Closing Date” means the date of this Agreement. 
 “Collateral” means the property described in Section 3. 

“Commitment Fee” means $20,000, which fee Lender received prior to the Closing Date, and shall be deemed fully earned on such
date regardless of the early termination of this Agreement. 
 “Confidential Information” has the meaning given to it
in Section 11.12. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect liability,
contingent or otherwise, of that Person with respect to (i) any Indebtedness of another, including any such obligation guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is
otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any
interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or
commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount

  
 2 

 
equal to the stated or determined amount of the primary obligation described in clauses (i) and (ii) above in respect of which such Contingent Obligation is made or, if not stated or
determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or
other support arrangement. 
 “Copyright License” means any written agreement granting any right to use any Copyright
or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Copyrights” means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or of any other country. 

“Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking
account, savings account, or certificate of deposit. 
 “ERISA” is the Employee Retirement Income Security Act of
1974, and its regulations, as amended and in effect from time to time. 
 “Event of Default” has the meaning given to
it in Section 9. 
 “Facility Charge” means 0.75% of the Maximum Term Loan Amount. 

“Financial Statements” has the meaning given to it in Section 7.1. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time,
provided that the parties agree that GAAP as in effect on the date of this Agreement shall be applicable for the interpretation of “capital lease obligations” in the definition of “Indebtedness”, unless the parties otherwise
agree in writing. 
 “Grant Document” means an instrument or agreement providing that the Borrower or another Person
or both shall provide funding for or share the costs of programs identified in such instruments or agreements entered into in the OCB. 
 “Grant Requirements” means all obligations of Borrower to provide funding for or share the costs of, programs identified in Grant Documents or to perform other obligations thereunder.

 “GSK Agreement” means that certain Research and Development Collaboration and License Agreement by and between
Glaxo Group Limited and Concert Pharmaceuticals dated May 29, 2009, as amended. 
 “Indebtedness” means
(a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within ninety (90) days), including reimbursement and other
obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 

  
 3 

 “Initial Public Offering” means an initial firm commitment underwritten offering
of Borrower’s common stock pursuant to a registration statement under the Securities Act of 1933 filed with and declared effective by the Securities and Exchange Commission. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other
bankruptcy or insolvency law, including assignments of all or substantially all of a Person’s assets for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or
other similar relief. 
 “Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents;
Licenses; trade secrets, proprietary information (including pre-clinical, clinical and other data) and inventions; mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill
associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith. 

“Interest Rate” means for any day a per annum rate of interest equal to the greater of either (i) 8.50% plus the United
States Prime Rate as reported in The Wall Street Journal minus 5.25%, and (ii) 8.50%; provided, however, the Interest Rate shall in no case exceed 11.0% per annum. 

“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any
Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person. 
 “Joinder Agreements” means for each Subsidiary (other than Concert Pharmaceuticals Securities Corp.), a completed and executed Joinder Agreement in substantially the form attached hereto as
Exhibit G. 
 “Lender” has the meaning given to it in the preamble to this Agreement. 

“License” means any Copyright License, Patent License, Trademark License or other license of rights or interests from a third
party. 
 “Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security
interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a
security interest. 
 “Loan” means the Advances made under this Agreement. 

  
 4 

 “Loan Documents” means this Agreement, the Notes, the ACH Authorization, the
Account Control Agreements, the Joinder Agreements, all UCC Financing Statements and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby (excluding the Warrant), as the same may from time
to time be amended, modified, supplemented or restated. 
 “Material Adverse Effect” means an occurrence, on or after
the date of the last set of audited financials, that has a material adverse effect upon: (i) the business, operations, properties, assets or condition (financial or otherwise) of the Borrower and its Subsidiaries, taken as a whole, other than
an effect in and of itself reasonably attributable to (a) adverse results or delays in any nonclinical or clinical trial, including without limitation failure to demonstrate the desired safety or efficacy of any biologic or drug; (b) the
denial, delay or limitation of approval of, or taking of any other regulatory action by, the United States Food and Drug Administration or any other governmental entity with respect to any biologic or drug; (c) a change in or discontinuation of
a strategic partnership or other collaboration or license arrangement; or (d) a going concern qualification in a financial statement or audit report resulting solely from Borrower and its Subsidiaries having less than twelve months of cash; or
(ii) the ability of Borrower to perform the Secured Obligations when due in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or
(iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens, in each case, in the aggregate; it being understood that in the case of each of items (ii) and (iii) the effects listed in clauses (i)(a)
through (d) of this definition shall be disregarded. 
 “Maturity Date” means July 1, 2015, provided
Maturity Date will mean October 1, 2015 if the interest-only period is extended pursuant to Section 2.1(d). 

“Maximum Term Loan Amount” means $20,000,000. 
 “Maximum Rate” shall have the meaning assigned to such term in Section 2.3. 
 “Note(s)” means a Term Note. 
 “OCB” means in the ordinary
course of business and shall include collaboration or licensing transactions that are customary in the Borrower’s industry such as, or comparable with or lesser in scope than, the Borrower’s existing collaboration with GlaxoSmithKline.

 “Patent License” means any written agreement granting any right with respect to any invention on which a Patent is
in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest. 

“Patents” means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all
registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country. 
 “Permitted Indebtedness” means: (i) Indebtedness of Borrower arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed
in Schedule 1A; (iii) Indebtedness in the principal amount of up to $200,000 

  
 5 

 
outstanding at any time secured by a lien described in clause (vii) of the defined term “Permitted Liens,”; (iv) Indebtedness to trade creditors incurred in the ordinary
course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement
obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $906,000 at any time outstanding; (viii) other Indebtedness in
an amount not to exceed $250,000 at any time outstanding; (ix) Contingent Obligations of up to $200,000 described on clause (iii) of the definition of Contingent Obligations entered into to mitigate risk and not for speculative purposes;
(x) Grant Requirements; (xi) Indebtedness among Borrowers or of Borrower to any non-Borrower Subsidiary; and (xii) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not
increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally
guaranteed by the United States of America or any agency or any State thereof maturing within twenty four months from the date of acquisition thereof, (b) commercial paper maturing no more than 270 days from the date of creation thereof and at
the time of the Investment having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000
maturing no more than twenty four months from the date of investment therein, (d) money market accounts; and (e) corporate debt obligations maturing no more than 24 months from the date of acquisition thereof and at the time of investment
having a rating of at least A3 or A- from either Standard & Poors or Moody’s Investor Service; (iii) repurchases of stock from former employees, directors, or consultants of Borrower under agreements approved by the
Borrower’s board of directors in an aggregate amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases; (iv) Investments accepted
in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not affiliates, in the
ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis
of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower’s Board of Directors; (viii) Investments
consisting of travel advances or moving expenses in the ordinary course of business; (ix) Investments in existing or newly-formed Subsidiaries organized in the United States, provided that such Subsidiaries enter into a Joinder Agreement and
execute such other documents as shall be reasonably requested by Lender and de minimis Investments in Concert Pharmaceuticals Securities Corporation in connection with its liquidation or dissolution; (x) Investments in subsidiaries organized
outside of the United States approved in advance in writing by Lender; (xi) licenses, joint ventures, collaboration agreements, strategic alliances and 

  
 6 

 
similar arrangements in the OCB providing for the exclusive or nonexclusive licensing of technology, Intellectual Property, or Borrower Products, the development of technology, Intellectual
Property or Borrower Products, the assignment of ownership or co-ownership rights in connection with the foregoing, or the providing of technical support, provided that any cash Investments by Borrower in another Person (other than a Subsidiary that
has entered into a Joinder pursuant to the terms hereof) as part of the foregoing do not exceed $100,000 in the aggregate in any fiscal year; (xii) Investments made pursuant to any investment policy adopted by a Borrower after the Closing Date
and approved by Lender; (xiii) Investments of up to $200,000 in the aggregate at any time outstanding in connection with Grant Requirements; (xiv) Investments by Borrower in another Borrower; and (xv) additional Investments that do
not exceed $250,000 in the aggregate per fiscal year. 
 “Permitted Liens” means any and all of the following:
(i) Liens in favor of Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in
good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other
like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in
circumstances which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and
other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than
for the repayment of borrowed money) or to secure statutory obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on
Equipment or software, other intellectual property, or other capital assets, constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”;
(viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted in the OCB and not interfering in any material respect with the business of the licensor;
(x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of
financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory, common law and contractual
rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real
property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under
clause (vii) of the definition of Permitted Indebtedness; (xv) Liens in connection with operating leases in the Equipment that is the subject of such leases; (xvi) Permitted Transfers; and (xvii) Liens incurred in connection with
the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in 

  
 7 

 
clauses (i) through (xvi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of
the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase. 

“Permitted Transfers” means (i) sales of Inventory in the normal course of business, (ii) exclusive or non-exclusive
licenses, joint ventures, collaboration agreements, strategic alliances and similar arrangements in the OCB providing for the exclusive or nonexclusive licensing of technology, Intellectual Property or Borrower Products, the development of
technology, Intellectual Property or Borrower Products, the assignment of ownership or co-ownership rights in connection with the foregoing, or the providing of technical support, (iii) dispositions of worn-out, obsolete or surplus Equipment at
fair market value in the ordinary course of business, (iv) Permitted Investments, (v) Permitted Liens, (vi) dispositions of Copyright rights in connection with publications in scientific journals, and (vii) other Transfers of
assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year. 
 “Person” means
any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government. 

“Preferred Stock” means at any given time any equity security issued by Borrower that has any rights, preferences or
privileges senior to Borrower’s common stock. 
 “Prepayment Charge” shall have the meaning assigned to such
term in Section 2.5. 
 “Receivables” means all of Borrower’s Accounts, Instruments, Documents, Chattel
Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights. 

“Secured Obligations” means Borrower’s obligations under this Agreement and any Loan Document, including any obligation
to pay any amount now owing or later arising. 
 “Subordinated Indebtedness” means Indebtedness subordinated to the
Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion. 

“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which
Borrower owns or controls more than 50% of the outstanding voting securities, including each entity listed on Schedule 1 hereto. 
 “Term Advance” means any Term Loan funds advanced under this Agreement. 

“Term Note” means a Promissory Note in substantially the form of Exhibit B-1. 

  
 8 

 “Trademark License” means any written agreement granting any right to use any
Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States
Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof. 
 “UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the Commonwealth of Massachusetts; provided, that in the event that, by reason of mandatory provisions of
law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the
Commonwealth of Massachusetts, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection,
priority or remedies and for purposes of definitions related to such provisions. 
 “Warrant” means the warrant
entered into in connection with the Loan. 
 Unless otherwise specified, all references in this Agreement or any Annex or
Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless
otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in
accordance with GAAP, consistently applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.

 SECTION 2. THE LOAN 
 2.1 Term Loan. 
 (a) Advances. Subject to the terms and conditions
of this Agreement, Lender will make, and Borrower agrees to draw, a Term Advance of $7,500,000 (the “First Tranche”) on the Closing Date. Beginning on the Closing Date, and continuing through March 31, 2012, Borrower may request one
additional Term Advance in an aggregate amount up to $12,500,000 (the “Second Tranche”). The aggregate outstanding Term Advances may be up to the Maximum Term Loan Amount. 

(b) Advance Request. To obtain a Term Advance, Borrower shall complete, sign and deliver an Advance Request (which, as to
the Second Tranche, shall be at least five business days before the Advance Date) and Term Note to Lender. Lender shall fund the Term Advance in the manner requested by the Advance Request provided that each of the conditions precedent in
Section 4 of this Agreement applicable to such Term Advance is satisfied as of the requested Advance Date. 

  
 9 

 (c) Interest. The principal balance of each Term Advance shall bear interest
thereon from such Advance Date at the Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Interest Rate will float and change on the day the Prime Rate changes from time
to time. 
 (d) Payment. Borrower will pay interest on each Term Advance in arrears on the first business day of
each month, beginning the month after the Advance Date and ending on January 3, 2013 (the “Interest Only Period”). Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the first anniversary of the
Closing Date in 30 equal monthly installments of principal and interest beginning February 1, 2013 and continuing on the first business day of each month thereafter. Notwithstanding the foregoing, Borrower may elect to postpone the date on
which the first such installment is due until May 1, 2013, (and the last payment date of the Interest Only Period shall be April 1, 2013), provided Borrower has begun the Proof of Concept study for CTP-499, meaning that the first patient
has been enrolled in a clinical study in which subjects with diabetes and reduced kidney function are randomly assigned to receive either placebo or CTP-499 treatment. The entire Term Loan principal balance and all accrued but unpaid interest
hereunder, shall be due and payable on Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the
Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each Term Note or Term Advance. 

2.2 Maximum Interest. Notwithstanding any provision in this Agreement, the Notes, or any other Loan Document, it is the
parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the Commonwealth of
Massachusetts shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an
amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to
the payment of principal outstanding on the Notes; second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured
Obligations are repaid, the excess (if any) shall be refunded to Borrower. 
 2.3 Default Interest. In the event
any payment is not paid on the scheduled payment date, an amount equal to five percent (5%) of the past due amount shall be payable on demand. Upon the occurrence and during the continuation of an Event of Default hereunder, all Secured
Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set 

  
 10 

 
forth in Section 2.1(c) plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear
interest on interest, compounded at the rate set forth in Section 2.1(c). 
 2.4 Prepayment. At its option
upon at least 7 business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding Advances by paying the entire principal balance, all accrued and unpaid interest, together with a prepayment charge equal to the
following percentage of the Advance amount being prepaid: if such Advance amounts are prepaid in any of the first twelve (12) months following the Closing Date, 3.0%; after twelve (12) months but prior to twenty four (24) months,
2.0%; and thereafter, 1.0% (each, a “Prepayment Charge”). Borrower agrees that the Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages
resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon demand of the Lender made no later than 30 days
following a Change in Control. 
 SECTION 3. SECURITY INTEREST 

3.1 As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the
Secured Obligations, Borrower grants to Lender a security interest in all of Borrower’s personal property now owned or hereafter acquired, including the following (collectively, the “Collateral”): (a) Receivables;
(b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property (but excluding thirty-five percent (35%) of the capital stock of any foreign Subsidiary
that constitutes a Permitted Investment); (g) Deposit Accounts; (h) Cash; (i) Goods; and other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, or acquired by, Borrower and wherever
located; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing. Notwithstanding any of the foregoing, the
Collateral shall not under any circumstance include, and no security interest is granted in (i) Borrower’s Intellectual Property, provided, however, that the Collateral shall include all Accounts and General Intangibles that consist
of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Borrower’s Intellectual Property (the “Rights to Payment”); (ii) any capital stock of any foreign subsidiary that
constitutes a Permitted Investment in excess of 65% of such capital stock, provided that Lender’s taking a security interest in more than 65% of such stock would be reasonably expected to cause Borrower to incur adverse tax consequences;
(iii) any assets of Borrower that both (x) consist of compounds and raw materials used to manufacture biopharmaceuticals or which are used for preclinical testing or clinical trials, and (y) are located outside of the United States,
if and for so long as the grant of such security interest is prohibited by or requires a consent under any applicable requirement of law of a jurisdiction other than the United States or any state or other subdivision thereof, provided that the
Borrower shall not be required to undertake any steps under the laws of any applicable foreign jurisdiction with respect to the creation, perfection or priority of the Secured Party’s security interests in such assets; (iv) equipment

  
 11 

 
financed by capital leases or purchase money financing and all Borrower’s books and records relating to the foregoing, and any and all claims, rights and interest in such assets and all
substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing; and (v) any cash or cash equivalents described in clause
(vii) of the definition of Permitted Indebtedness. Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security
interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Lender’s security interest in the
Rights to Payment, except to the extent that such inclusion as Collateral could be inconsistent with or conflict with the GSK Agreement or any agreement entered into in connection with a Permitted Transfer or interfere with the parties’ rights
and remedies thereunder. 
 SECTION 4. CONDITIONS PRECEDENT TO LOAN 

The obligations of Lender to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions: 

4.1 Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Lender the following: 

(a) executed originals of the Loan Documents, Account Control Agreements, a legal opinion of Borrower’s counsel, and
all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in all cases in form and substance reasonably
acceptable to Lender; 
 (b) certified copy of resolutions of Borrower’s board of directors evidencing
approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby; 
 (c) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower; 

(d) a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other
jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 
 (e) payment of the Facility Charge and reimbursement of Lender’s current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; and 

(f) such other documents as Lender may reasonably request. 

  
 12 

 4.2 All Advances. On each Advance Date: 

(a) Lender shall have received an Advance Request and a Note for the relevant Advance as required by Section 2.1(b),
as applicable, each duly executed by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer. 
 (b) The representations and warranties set forth in this Agreement and in Section 5 of this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same
effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. 
 (c) Borrower shall be in compliance in all material respects with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of
and immediately after such Advance no Event of Default shall have occurred and be continuing. 
 (d) Each Advance
Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance
Request. 
 4.3 No Default. As of the Closing Date and each Advance Date, as applicable, (i) no fact or
condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no Material Adverse Effect has occurred and is continuing. 

SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER 

Borrower represents and warrants that: 
 5.1 Corporate Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all
jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Borrower’s present name, former
names (if any), owned and leased locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including
any Compliance Certificate) provided to Lender after the Closing Date. 
 5.2 Collateral. Borrower owns its
property, free of all Liens, except for Permitted Liens. Borrower has the corporate power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations. 

5.3 Consents. Borrower’s execution, delivery and performance of the Notes, this Agreement and all other Loan
Documents, and Borrower’s execution of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted

  
 13 

 
Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate of Incorporation, bylaws, or any material law,
regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any material contract or agreement or require the consent or approval of any other Person that has
not been obtained. The individual or individuals executing the Loan Documents and the Warrant on behalf of the Borrower are duly authorized to do so. 
 5.4 Material Adverse Effect. No Material Adverse Effect has occurred and is continuing. 
 5.5 Actions Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or proceedings at law or in equity by or before any governmental authority now pending or, to
the knowledge of Borrower, threatened in writing against or affecting Borrower or its property as to which there is a reasonable likelihood of an adverse determination and which, if adversely determined, would reasonably be expected to, individually
or in the aggregate, result in a Material Adverse Effect. 
 5.6 Laws; Agreements. Borrower is not in violation
of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in
default in any manner under any provision of any agreement or instrument evidencing Indebtedness, or any other material agreement to which it is a party or by which it is bound, and which default would reasonably be expected to have a Material
Adverse Effect. 
 5.7 Information Correct and Current. No report, Advance Request, financial statement, exhibit
or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto, when taken together with all such other reports, statements or other documents or writings, contains
any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading at the time such statement was made or deemed made.
Additionally, any and all financial or business projections provided by Borrower to Lender shall be at the time delivered (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the
most current of such projections provided to Borrower’s Board of Directors. 
 5.8 Tax Matters. Except as
described on Schedule 5.8, (a) Borrower has filed all material federal, state and local tax returns that it is required to file (or extensions thereof), (b) Borrower has duly paid or fully reserved (if required under GAAP) for all material
taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any material tax assessment received by Borrower for the
three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings). 

  
 14 

 5.9 Intellectual Property Claims. Except for Permitted Liens, Borrower is
the sole owner of, or otherwise has the right to use, the Intellectual Property material to its business. Except as described on Schedule 5.9,(i) to Borrower’s knowledge, each of the material issued Copyrights, Trademarks and Patents is valid
and enforceable, (ii) no material Intellectual Property of Borrower has been judged by a decision of a court of competent jurisdiction, invalid or unenforceable, in whole or in part, and (iii) no claim has been made to Borrower in writing
that any material Intellectual Property of Borrower violates the rights of any third party except to the extent such claim would not reasonably be expected to cause a Material Adverse Effect. Exhibit D is a true, correct and complete list of each of
Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (shrink-wrap software licenses and click on license agreements, open source code
and other licenses available to the public without customization shall not be considered a material License or agreement), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the
Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract,
license or agreement is in material breach thereof or has failed to perform any material obligations thereunder in each case which would reasonably be expected to have a Material Adverse Effect. 

5.10 Intellectual Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business,
will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing,
other than in connection with Permitted Transfers, and in the case of material in-bound Licenses, except for restrictions that are unenforceable under Division 9 of the UCC and except as provided in the GSK Agreement, Borrower has the right, to the
extent required to operate Borrower’s business, to freely transfer, license or assign the Intellectual Property licensed pursuant to such material License without condition, restriction or payment of any kind (other than payments in the
ordinary course of business) to any third party, Borrower owns or has the right to use, pursuant to valid licenses, all material software development tools, library functions, compilers and other third-party software and other items that are
necessary for the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products that are currently being clinically developed, manufactured or sold by Borrower. For the avoidance of doubt,
shrink-wrap licenses, click on license agreements, open source code and other licenses available to the public without customization shall not be considered a material License. 

5.11 Borrower Products. Except as described on Schedule 5.11, no material Intellectual Property owned by Borrower or
Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened (in writing) litigation, inter-party proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding
foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any material respect Borrower’s use, 

  
 15 

 
transfer or licensing thereof or that may affect the validity, use or enforceability thereof. To Borrower’s knowledge, there is no decree, order, judgment, agreement, stipulation, arbitral
award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future material Intellectual Property related to the operation or conduct of the business of
Borrower or Borrower Products. Borrower has not received any written notice or claim challenging Borrower’s ownership in any material Intellectual Property (or written notice of any claim challenging the ownership in any material licensed
Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto. To Borrower’s knowledge, neither Borrower’s use of its material Intellectual Property nor
the production and sale of Borrower Products infringes in any material respect the Intellectual Property or other rights of others. 
 5.12 Financial Accounts. Exhibit E, as may be updated by the Borrower in a written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other
financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies in all
material respects the name, address and telephone number of each bank or other institution, the name in which the account is held, and the complete account number therefor. 

5.13 Employee Loans. Except as permitted as a Permitted Investment, Borrower has no outstanding loans to any employee,
officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party. 

5.14 Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14
annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date,
is a true, correct and complete list of each Subsidiary. 
 SECTION 6. INSURANCE; INDEMNIFICATION 

6.1 Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence
form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms
of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance (including umbrella coverage) for each occurrence. Borrower has and agrees to maintain a minimum of
$2,000,000 of directors and officers’ insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral,
insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. Borrower shall also
carry and maintain a fidelity insurance policy in an amount not less than $100,000. 

  
 16 

 6.2 Certificates. Borrower shall deliver to Lender certificates of insurance
that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance certificate shall state Lender is an additional insured for commercial
general liability, an additional insured and a loss payee for all risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity insurance, and a loss payee for property insurance and additional insured for
liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk
property damage insurance and fidelity. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation (except for 10 days for non payment). Any failure of Lender to scrutinize such
insurance certificates for compliance is not a waiver of any of Lender’s rights, all of which are reserved. 

6.3 Indemnity. Borrower agrees to indemnify and hold Lender and its officers, directors, employees, agents, in-house
attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict
liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be instituted or asserted against or incurred by Lender or any such
Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and
thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting from Lender’s or any indemnitee’s gross negligence or
willful misconduct. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by
the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement; provided, however, that (i) with respect to such liabilities imposed originally and independently on Lender,
Lender shall notify a Borrower of any such liabilities within 180 days of the initial date Lender had actual knowledge of Lender’s direct exposure to such liabilities, and (ii) with respect to all other such liabilities not described in
subsection (i), Lender shall notify Borrower of any such liabilities within 180 days of the initial date Lender has actual knowledge of its direct exposure to such liabilities. 

SECTION 7. COVENANTS OF BORROWER 
 Borrower agrees as follows: 
 7.1 Financial Reports. Borrower shall
furnish to Lender the financial statements and reports listed hereinafter (the “Financial Statements”): 
 (a) as soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated
basis, if applicable), including balance sheet and related statements of income and cash flows, all certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that
they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject
to adjustment with respect to revenue recognition for upfront and milestone payments. 

  
 17 

 (b) as soon as practicable (and in any event within 45 days) after the end
of each of the first three calendar quarters of each year (I) unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated basis, if applicable), including balance sheet and related
statements of income and cash flows, certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except
(i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for
upfront and milestone payments; and (II) before an Initial Public Offering, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options. 

(c) (I) as soon as practicable and in any event within sixty (60) days after the end of each fiscal year,
preliminary financial statements as of the end of such fiscal year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, certified on behalf of Borrower by Borrower’s Chief
Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments,
(iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for upfront and milestone payments; (II) before an Initial Public Offering, as soon as practicable and in
any event within sixty (60) days after the end of each fiscal year, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options; and (III) as soon as practicable and in any event
within one hundred eighty (180) days) after the end of each fiscal year, audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and
cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Lender, accompanied by an
audit report from such accountants which is unqualified as to scope of audit; 
 (d) as soon as practicable (and
in any event within 30 days) after the end of each month, a Compliance Certificate in the form of Exhibit F; 

  
 18 

 (e) promptly after the sending or filing thereof, as the case may be, copies
of any proxy statements, financial statements or reports that Borrower has made available generally to holders of its Preferred Stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the
Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange; 
 (f) Before an Initial Public Offering, at the same time and in the same manner as it gives to its Board of Directors, copies of all notices, minutes, consents and other materials that Borrower provides to
its Board of Directors in connection with meetings of the Board of Directors, and minutes of such meetings, provided Borrower may exclude from such delivery any materials, the disclosure of which would reasonably be expected to constitute or effect
a waiver of the attorney-client privilege; 
 (g) financial and business projections promptly following their
approval by Borrower’s Board of Directors, as well as budgets, operating plans; and 
 (h) other financial
information reasonably requested by Lender. 
 Borrower shall not make any change in its fiscal years or fiscal quarters or,
without notice to Lender, any change in its accounting policies or reporting practices. The fiscal year of Borrower shall end on December 31. 
 The executed Compliance Certificate may be sent via facsimile to Lender at (650) 473-9194 or via e-mail to jbourque @herculestech.com. All Financial Statements required to be delivered pursuant to
clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to jbourque@herculestech.com provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible,
they shall be sent via facsimile to Lender at: (866) 468-8916, attention Chief Credit Officer. 
 7.2
Management Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at
reasonable times and upon reasonable notice during normal business hours (but in any event no more than once in any12-month period unless an Event of Default has occurred and is continuing). In addition, any such representative shall have the right
to meet with management and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning
significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute “management rights” within the
meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over
Borrower’s management or policies. 

  
 19 

 7.3 Further Assurances. Borrower shall from time to time execute, deliver
and file, alone or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other necessary documents to perfect or give to Lender a first priority Lien on the Collateral (subject to
Permitted Liens). Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and
protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control
agreements, security agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall in its reasonable business judgment protect and
defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens. 

7.4 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any
Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness at any time before the Maturity Date, except for the
conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion. 
 7.5 Encumbrances. Borrower shall at all times keep its property free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice when the Borrower knows
of any legal process affecting such property, or any Liens thereon. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its property from and against all Persons claiming any interest adverse to such
Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice when the Borrower knows of
any legal process affecting such Subsidiary’s property. Borrower shall not enter into any agreement with any Person other than Lender (other than in connection with Permitted Liens and Permitted Transfers) that has the effect of restricting
Borrower from granting a Lien on its Intellectual Property to Lender. 
 7.6 Investments. Borrower shall not
directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do, other than Permitted Investments. 
 7.7 Distributions. Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than (i) pursuant to employee, director
or consultant repurchase plans or other similar agreements, in an aggregate amount not to exceed $250,000, or (ii) pursuant to Section 4 of the Third Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of
June 1, 2009 provided that any such repurchase is approved by the Borrower’s Board of Directors, in an aggregate amount not to exceed $500,000, (b) declare or pay any cash dividend or

  
 20 

 
make a cash distribution on any class of stock or other equity interest, except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees,
officers or directors or guarantee the payment of any such loans granted by a third party other than Permitted Investments. 
 7.8 Transfers. Except for Permitted Transfers, Permitted Investments and Permitted Liens, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey
any equitable, beneficial or legal interest in any material portion of their assets. 
 7.9 Mergers or
Acquisitions. (a) Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or
into Borrower), (b) Borrower shall not acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person other than Permitted Investments. Borrower may dissolve any Subsidiary as
long as the assets of that Subsidiary are promptly distributed to such Subsidiary’s shareholder. 
 7.10
Taxes. Borrower and its Subsidiaries shall pay when due all material taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the
Collateral or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal property tax
returns (or extensions) in respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP.

 7.11 Corporate Changes. 

(a) Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without
twenty (20) days’ prior written notice to Lender. 
 (b) The Borrower shall not suffer a Change in
Control. 
 (c) Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal
place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States. 
 (d) Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (v) Borrower Products, including compounds and raw materials used to manufacture biopharmaceuticals or which
are used for preclinical testing or clinical trials, in the ordinary course of business, (w) Permitted Transfers, (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up
to $150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has 

  
 21 

 
provided prompt written notice to Lender, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third party bailee, and the Collateral has a
value in excess of $250,000, it has delivered a bailee agreement in form and substance reasonably acceptable to Lender. 
 7.12 Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts constituting Collateral (other than payroll accounts or accounts holding trust fund taxes), or accounts
holding Investment Property constituting Collateral, except with respect to which Lender has an Account Control Agreement, if applicable. 
 7.13 Subsidiaries. Borrower shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 15 days of formation, shall cause any such Subsidiary organized under the laws of any
State within the United States to execute and deliver to Lender a Joinder Agreement. 
 SECTION 8. RESERVED

 8.1 Reserved. 
 SECTION 9. EVENTS OF DEFAULT 
 The occurrence of any one or more of
the following events shall be an Event of Default: 
 9.1 Payments. Borrower fails to pay any amount due under
this Agreement, the Notes or any of the other Loan Documents on the due date, and in each case such default continues for more than 3 business days after the due date thereof; or 

9.2 Covenants. Borrower breaches or defaults in the performance of any covenant under any of the Loan Documents, and
(a) with respect to a default under any such covenant under this Agreement (other than under Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.11) such default continues for more than ten (10) business days after the earlier of the date on which
(i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default, or (b) with respect to a default under any of Sections 6.1, 7.5, 7.6, 7.7, 7.8 or 7.9, (b) the occurrence of such
default, or (c) with respect to a default under any of Sections 7.9(a) and 7.11(b), the Lender has given notice of such default to Borrower no later than 30 days after a Change of Control; or 

9.3 Material Adverse Effect. An event has occurred that would reasonably be expected to have a Material Adverse Effect; or

 9.4 Other Loan Documents. The occurrence of any default under any Loan Document, the Warrant or any other
agreement between Borrower and Lender and such default continues for more than ten business (10) days after the earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default;
or 

  
 22 

 9.5 Representations. Any representation or warranty made by Borrower in any
Loan Document or in the Warrant shall have been false or misleading in any material respect; or 
 9.6
Insolvency. Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay the Secured Obligations under the Loan Documents, or shall become
insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar
relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part
(i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted for 3 consecutive business days, or terminate substantially all of its employees; or
(vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) sixty (60) days shall have expired after the
commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being
dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be
timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter
a decree or order granting the relief sought in any such proceedings; or (v) forty five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower
or of all or any substantial part of the properties of Borrower without such appointment being vacated; or 
 9.7
Attachments; Judgments. Any portion of Borrower’s assets having a value in excess of $350,000 is attached or seized, or a levy is filed against any such assets, or a judgment or judgments (not covered by insurance as to which an insurer not
affiliated with Borrower has acknowledged coverage) is/are entered for the payment of money, individually or in the aggregate, of at least $350,000, and remains unstayed, unbonded and unsatisfied for more than 30 days, or Borrower is enjoined or in
any way prevented by court order from conducting any material part of its business; or 
 9.8 Other Obligations.
The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness in excess of $175,000. 

SECTION 10. REMEDIES 
 10.1 General. Upon and during the continuance of any one or more Events of Default, (i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations together
with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of 

  
 23 

 
the type described in Section 9.6, the Notes and all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act),
and (ii) Lender may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account on Borrower’s behalf and endorse Lender’s name without recourse on any such payment for
deposit directly to Lender’s account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold,
sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not
exclusive. 
 10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of
Default, Lender may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or
processing, in such order as Lender may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’
prior written notice to Borrower. Lender may require Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or
other realization upon all or any part of the Collateral shall be applied by Lender in the following order of priorities: 

First, to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and advisors’ fees and expenses
as described in Section 11.11; 
 Second, to Lender in an amount equal to the then unpaid amount of the Secured Obligations
(including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and 
 Finally, after the full and final payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of
competent jurisdiction may direct. 
 Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the
Collateral if it complies with the obligations of a secured party under the UCC. 
 10.3 The Lender agrees not to
issue a notice of exclusive control or any other instruction under any Account Control Agreement unless an Event of Default has occurred and is continuing. 
 10.4 No Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Lender to
marshal any Collateral. 
 10.5 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be
in addition to all rights, powers and remedies given by statute or rule of 

  
 24 

 
law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other
rights, powers and remedies of Lender. 
 SECTION 11. MISCELLANEOUS 

11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 11.2 Notice.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) (a “Notification”) that is required, contemplated,
or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by
facsimile or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed
to the party to be notified as follows: 
 (a) If to Lender: 

HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

Legal Department 
 Attention: Chief Legal Officer and Janice Bourque 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 

Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
 With a copy to: 

HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

31 St. James Ave., Suite 790 
 Boston, MA 02116 
 Attention: Janice Bourque 

Facsimile:
617-                     
 Telephone: 617-314-9992 
 (b) If to Borrower: 

CONCERT PHARMACEUTICALS, INC. 

99 Hayden Ave., Suite 500 
 Lexington, MA 02421 
 Attention: Nancy Stuart 

Chief Operating Officer 
 Facsimile: 
 Telephone: 

  
 25 

 With a copy (that shall not constitute notice) to: 

Wilmer Cutler Pickering Hale and Dorr LLP. 

60 State Street 
 Boston, MA 02446 
 Attention: David E. Redlick 

Facsimile: 617-526-5000 
 Telephone: 617-526-6000 
 or to such other address as each party may designate for
itself by like notice. Any notification delivered to a party to this Agreement in accordance with this Section shall be valid notwithstanding any failure to deliver a copy thereof to a Person not party to this Agreement. 

11.3 Entire Agreement; Amendments. This Agreement, the Notes, and the other Loan Documents constitute the entire agreement
and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or
oral, with respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated October 12, 2011). None of the terms of this Agreement, the Notes or any of the other Loan Documents may be amended except by an
instrument executed by each of the parties hereto. 
 11.4 No Strict Construction. The parties hereto have
participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 11.5 No Waiver. The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any
duty upon Lender to exercise any such powers. No omission or delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated,
shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in any way affect the right of Lender to enforce such provisions thereafter. 

11.6 Survival. All agreements, representations and warranties contained in this Agreement, the Notes and the other Loan
Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this Agreement and Section 6.3 and any provisions that, by their express terms are to survive
the expiration or other termination of this Agreement shall survive such expiration or termination. 

  
 26 

 11.7 Successors and Assigns. The provisions of this Agreement and the other
Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Notes or any of the other Loan Documents without Lender’s express
prior written consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents to an Assignee (defined in Section 11.13) without prior
notice to Borrower or Borrower’s consent, and all of such rights shall inure to the benefit of Lender’s successors and assigns. 
 11.8 Governing Law. This Agreement, the Notes and the other Loan Documents have been negotiated and delivered to Lender in the Commonwealth of Massachusetts, and shall have been accepted by Lender in the
Commonwealth of Massachusetts. Payment to Lender by Borrower of the Secured Obligations is due in the Commonwealth of Massachusetts. This Agreement, the Notes and the other Loan Documents shall be governed by, and construed and enforced in
accordance with, the laws of the Commonwealth of Massachusetts, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of
Section 11.10 is not applicable) arising in or under or related to this Agreement, the Notes or any of the other Loan Documents may be brought in any state or federal court located in the Commonwealth of Massachusetts. By execution and delivery
of this Agreement, each party hereto generally and unconditionally: (a) consents to exclusive personal jurisdiction in Suffolk County, Commonwealth of Massachusetts; (b) waives any objection as to jurisdiction or venue in the Business
Litigation Session of the Suffolk Superior Court, Suffolk County, Commonwealth of Massachusetts; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by
any judgment rendered thereby in connection with this Agreement, the Notes or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with
the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the
right of either party to bring proceedings in the courts of any other jurisdiction. 
 11.10 Mutual Waiver of
Jury Trial / Judicial Reference. 
 (a) Because disputes arising in connection with complex financial
transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a
judge applying such applicable laws. EACH OF BORROWER AND LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, 

  
 27 

 
COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This
waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between Borrower and Lender; and any Claims for damages, breach of
contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document. 
 11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing
costs, and other reasonable miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other reasonable professionals’ fees and expenses incurred by Lender after the Closing Date in connection with
or related to: (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents;
(e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in
connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to
Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof. 

11.12 Confidentiality. Lender acknowledges that certain items of Collateral and information provided to Lender by Borrower
are confidential or proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential, proprietary or secret by Borrower at the time of disclosure, or (y) should reasonably be understood to be
confidential, proprietary or secret (the “Confidential Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, perfecting or enforcing Lender’s security
interest in the Collateral or otherwise shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information:
(a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its controlled affiliates if Lender in its sole discretion determines that any such party should have access to such information in
connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this
paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public without any disclosure by
Lender or breach of this Section 11.12; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if required or appropriate
in 

  
 28 

 
response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or
law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral during the continuation of
an Event of Default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior
to disclosure; or (h) otherwise with the prior written consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or any guarantor under this
Agreement or the other Loan Documents. 
 11.13 Assignment of Rights. Borrower acknowledges and understands that
Lender may sell and assign all or part of its interest hereunder and under the Note(s) and Loan Documents (an “Assignment”) to any person or entity provided that (a) no such Assignment shall be made to a competitor of the Borrower,
and (b) Lender will not make any Assignment to a Person organized or resident outside the United States without Borrower’s consent which shall not be unreasonably withheld (such assignee, an “Assignee” or “assignee”).
After such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so
assigned; but with respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall relieve Borrower of any of its obligations hereunder. No such Assignment shall
release the Lender from its obligations to fund the Term Advance subject to the terms and conditions contained in Section 2.1 hereof. Lender agrees that in the event of any transfer by it of the Note(s), it will endorse thereon a notation as to
the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon. 

11.14 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and
continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any
significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or
reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or
returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral
had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or
documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash. 

  
 29 

 11.15 Counterparts. This Agreement and any amendments, waivers, consents or
supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the
same instrument. 
 11.16 No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor
will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all
provisions of the Loan Documents will be personal and solely between the Lender and the Borrower. 
 11.17
Publicity. Subject to applicable law, Lender may use Borrower’s name and logo, and include a brief description of the relationship between Borrower and Lender, in Lender’s marketing materials, provided that the Borrower shall have the
right to review such use prior to publication. 
 (SIGNATURES TO FOLLOW) 

  
 30 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	CONCERT PHARMACEUTICALS, INC.
		
	Signature:	 	/s/ Roger D. Tung
		 	  

		
	Print Name:	 	Roger D. Tung
		
	Title:	 	Chief Executive Officer

 Accepted in Boston, Massachussets: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	  

	Name:	 	  

	Its:	 	  

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

							
		 		 	   BORROWER:
			
		 		 	   CONCERT PHARMACEUTICALS, INC.
				
		 		 	   Signature:	 	  

				
		 		 	   Print Name:	 	  

				
		 		 	   Title:	 	  

				
	Accepted in Boston, Massachussets:	 		 		 	

  

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	/s/ K. Nicholas Martitsch
		 	  

	Name:	 	 K. Nicholas Martitsch

	Its:	 	 Associate General Counsel

  
 31 

 Table of Exhibits and Schedules 

 

			
	Exhibit A:	  	Advance Request
		  	Attachment to Advance Request
		
	Exhibit B-1:	  	Term Note
		
	Exhibit C:	  	Name, Locations, and Other Information for Borrower
		
	Exhibit D:	  	Borrower’s Patents, Trademarks, Copyrights and Licenses
		
	Exhibit E:	  	Borrower’s Deposit Accounts and Investment Accounts
		
	Exhibit F:	  	Compliance Certificate
		
	Exhibit G:	  	Joinder Agreement
		
	Exhibit H:	  	ACH Debit Authorization Agreement
		
	Schedule 1	  	Subsidiaries
	Schedule 1A	  	Existing Permitted Indebtedness
	Schedule 1B	  	Existing Permitted Investments
	Schedule 1C	  	Existing Permitted Liens
	Schedule 5.3	  	Consents, Etc.
	Schedule 5.5	  	Actions Before Governmental Authorities
	Schedule 5.8	  	Tax Matters
	Schedule 5.9	  	Intellectual Property Claims
	Schedule 5.10	  	Intellectual Property
	Schedule 5.11	  	Borrower Products
	Schedule 5.14	  	Capitalization

  
 1 

 EXHIBIT A 
 ADVANCE REQUEST 
  

			
	To:	  	Date:                           
             , 201  

 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 

Attn: Janice Bourque 

CONCERT PHARMACEUTICALS, INC. (“Borrower”) hereby requests from Hercules Technology Growth Capital, Inc. (“Lender”) an Advance
in the amount of          Dollars ($        ) on
                    ,              (the “Advance Date”) pursuant to the Loan
and Security Agreement between Borrower and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 

Please: 
  

									
	(a)	  	Issue a check payable to Borrower	  	  
	  	
				
		  	or	  		  	
				
	(b)	  	Wire Funds to Borrower’s account	  	  
	  	
				
		  	Bank:	  	  
	  	
		  	Address:	  	  
	  	
		  		  	  
	  	
		  	ABA Number:	  	  
	  	
		  	Account Number:	  	  
	  	
		  	Account Name:	  	  
	  	

 Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be
satisfied upon the making of such Advance, including but not limited to: (i) that no Material Adverse Effect has occurred and is continuing; (ii) No Material Adverse Effect has occurred and is continuing; (iii) that the
representations and warranties set forth in the Agreement are true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and
warranties expressly relate to an earlier date; (iv) that Borrower is in compliance in all material respects with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (v) that as of the
Advance Date, no fact or condition exists that constitutes (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right
to review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance if such representation is not true and correct in all material respects.

  
 2 

 Borrower hereby represents that the information described in Exhibit C to the Loan Agreement
have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. 
 Borrower agrees to notify Lender promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Borrowing Date and if Lender has
received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date. 

Executed as of                     ,
201  . 
  

			
	BORROWER:
	
	CONCERT PHARMACEUTICALS, INC.
		
	SIGNATURE:	 	  

 

			
	TITLE:	 	  

 

			
	PRINT NAME:	 	  

  
 3 

 ATTACHMENT TO ADVANCE REQUEST 

Dated:                     

 Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

			
	Name:	  	CONCERT PHARMACEUTICALS, INC.
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware
		
	Organization file number:	  	4141420

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its
current owned and leased locations are as follows: 

  
 4 

 EXHIBIT B-1 
 SECURED TERM PROMISSORY NOTE 
  

			
	$        	  	Advance Date:                     ,
201  
		
		  	Maturity Date: July 1, 2015

 FOR VALUE RECEIVED, CONCERT PHARMACEUTICALS, INC., a Delaware corporation (the
“Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc. or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the
holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of         
($        ) or such other principal amount as Lender has advanced to Borrower, together with interest at a floating rate equal to the greater of (a) 8.50% per annum and (b) 8.50% plus the United
States Prime Rate as reported in The Wall Street Journal minus 5.25%, not in any case to exceed 11.0% per annum, based upon a year consisting of 360 days, with interest computed daily based on the actual number of days in each month.

 This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and
Security Agreement dated December     , 2011, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is
entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in
accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this
Promissory Note. 
 Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of protest under
the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender
and is payable in the Commonwealth of Massachusetts. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts, excluding any conflicts of law rules or principles that
would cause the application of the laws of any other jurisdiction. 
  

							
	BORROWER:	 		 	CONCERT PHARMACEUTICALS, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

 EXHIBIT C 
 NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER 
 1. Borrower
represents and warrants to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows: 
  

			
	Name:	  	CONCERT PHARMACEUTICALS, INC.
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware
		
	Organization file number:	  	4141420

 2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date,
Borrower did not do business under any other name or organization or form except the following: 
 Name: Concert Pharmaceuticals,
Inc. 
 Used during dates of: Five (5) years prior to the Closing 

Type of Organization: Corporation 
 State of organization: Delaware 
 Organization file Number: 4141420 

Borrower’s fiscal year ends on: December 31 
 Borrower’s federal employer tax identification number is: 20-4839882 
 3.
Borrower represents and warrants to Lender that its chief executive office is located at 99 Hayden Avenue, Suite 400 & 500, Lexington, MA 02421. 

 EXHIBIT D 
 BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES 
 See attached. 

							
	 	  	Title	  	Application Number	  	Filing Date
				
	1	  	4-Hydroxybutyric Acid Analogs	  		  	
		  	 United States of America
	  	61/442451	  	February 14, 2011
		  	 United States of America
	  	61/484296	  	May 10, 2011
		  	 Canada
	  	2740247	  	May 13, 2011
		  	 Australia
	  	2011200745	  	February 22, 2011
		  	 Canada
	  	2732479	  	February 23, 2011
		  	 Australia
	  	2011202741	  	June 8, 2011
				
	2	  	4-Hydroxybutyric Acid Analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/031981	  	April 22, 2010
		  	 Australia
	  	 2010239244
	  	October 23, 2011
		  	 European Patent Convention
	  	10716196	  	October 23, 2011
		  	 United States of America
	  	 13/265609
	  	October 23, 2011
		  	 Canada
	  	NEW APPLICATION	  	October 23, 2011
		  	 India
	  	 8456/DELNP/2011
	  	October 23, 2011
				
	3	  	Alpha 1A-adrenoceptor antagonists	  		  	
		  	 United States of America
	  	12/072,501	  	February 26, 2008
		  	 United States of America
	  	12/550864	  	February 26, 2008
		  	 United States of America
	  	13/189080	  	July 22, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2008/002513	  	February 26, 2008
		  	 European Patent Convention
	  	8726096.4	  	February 26, 2008
				
	4	  	Analogues of cilostazol	  		  	
		  	 United States of America
	  	12/150107	  	April 24, 2008
		  	 United States of America
	  	12/644758	  	December 22, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2008/005301	  	April 24, 2008
		  	 European Patent Convention
	  	8743256.3	  	April 24, 2008
				
	5	  	Carbamoylpyridone derivatives	  		  	
		  	 United States of America
	  	61/481977	  	May 3, 2011
				
	6	  	Derivatives of dimethylcurcumin	  		  	
		  	 United States of America
	  	13/049481	  	March 16, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/028631	  	March 16, 2011
				
	7	  	Deuterated 2-amino-3-hydroxypropanoic acid derivatives	  		  	
		  	 United States of America
	  	13/119318	  	March 16, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/057001	  	September 15, 2009
		  	 European Patent Convention
	  	9792561.4	  	September 15, 2009
				
	8	  	Deuterated Benzo[D][1,3]-dioxol derivatives	  		  	
		  	 United States of America
	  	12/688466	  	January 15, 2010

  
 Page 1 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	9	  	Deuterated CFTR potentiators	  		  	
		  	 United States of America
	  	61/487497	  	May 18, 2011
				
	10	  	Deuterated fingolimod	  		  	
		  	 United States of America
	  	12/290645	  	October 31, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/012390	  	October 31, 2008
		  	 European Patent Convention
	  	8847117.2	  	October 31, 2008
		  	 Hong Kong
	  	11101551.6	  	
		  	 Japan
	  	2010-532064	  	October 31, 2008
		  	 United States of America
	  	13/311171	  	05-Dec-2011
				
	11	  	Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/038577	  	June 15, 2010
		  	 Australia
	  	instructions to file sent	  	December 6, 2011
		  	 Brazil
	  	instructions to file sent	  	December 6, 2011
		  	 Canada
	  	instructions to file sent	  	December 6, 2011
		  	 China (People’s Republic)
	  	201010620532.7	  	December 22, 2010
		  	 Eurasian Patent Organization
	  	instructions to file sent	  	December 6, 2011
		  	 European Patent Convention
	  	instructions to file sent	  	December 6, 2011
		  	 India
	  	instructions to file sent	  	December 6, 2011
		  	 Japan
	  	instructions to file sent	  	December 6, 2011
		  	 Korea, Republic of
	  	10-2010-0132933	  	December 22, 2010
				
	12	  	Substituted isoindoline-1,3-dione derivatives	  		  	
		  	 United States of America
	  	12/816295	  	June 15, 2010
		  	 Korea, Republic of
	  	10-2010-0132933	  	December 22, 2010
		  	 China (People’s Republic)
	  	2.01011E+11	  	December 22, 2010
				
	13	  	Deuterated pyridinones	  		  	
		  	 United States of America
	  	13/132784	  	December 3, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/066606	  	December 3, 2009
				
	14	  	Fluorinated diaryl urea derivatives	  		  	
		  	 United States of America
	  	13/320646	  	15-Nov-2011
		  	 Patent Cooperation Treaty
	  	PCT/US2010/035655	  	May 20, 2010
				
	15	  	Fluorouracil derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/026436	  	February 28, 2011
				
	16	  	Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050134	  	September 1, 2011

  
 Page 2 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	17	  	Niacin prodrugs and deuterated versions thereof	  		  	
		  	 United States of America
	  	12/948484	  	November 17, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/057051	  	November 17, 2010
				
	18	  	Novel benzo[D][1,3]-dioxol derivatives	  		  	
				
		  	 Patent Cooperation Treaty
	  	PCT/US2006/029599	  	July 28, 2006
		  	 Australia
	  	2006275595	  	July 28, 2006
		  	 Brazil
	  	PI0615973-7	  	July 28, 2006
		  	 Canada
	  	2616383	  	July 28, 2006
		  	 China (People’s Republic)
	  	2.0068E+11	  	July 28, 2006
		  	 Eurasian Patent Organization
	  	200800490	  	July 28, 2006
		  	 European Patent Convention
	  	6813250.5	  	July 28, 2006
		  	 Hong Kong
	  	8111437	  	July 28, 2006
		  	 India
	  	607/DELNP/2008	  	July 28, 2006
		  	 Japan
	  	2008-524227	  	July 28, 2006
		  	 Korea, Republic of
	  	10-2008-7004867	  	July 28, 2006
		  	 Mexico
	  	MX/a/2008/001193	  	July 28, 2006
		  	 Philippines
	  	1-2008-500121	  	July 28, 2006
		  	 South Africa
	  	2008/00785	  	July 28, 2006
		  	 United States of America
	  	11/704554	  	February 8, 2007
				
	19	  	Novel tetrahydro-1H-pyrido[4,3-B]indoles	  		  	
		  	 United States of America
	  	12/625059	  	November 24, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/065872	  	November 25, 2009
				
	20	  	Oxazolidinone derivatives and methods of use	  		  	
		  	 United States of America
	  	12/214260	  	June 17, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2007/022516	  	October 23, 2007
		  	 Hong Kong
	  	10102539.2	  	October 23, 2007
		  	 Japan
	  	2009-533406	  	October 23, 2007
				
	21	  	Polymorphs of (S)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1H-purine-2,6(3H,7H)-dione	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050229	  	September 1, 2011
				
	22	  	Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050138	  	September 1, 2011

  
 Page 3 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	23	  	Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050139	  	September 1, 2011
				
	24	  	Prostacyclin analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2009/003801	  	June 26, 2009
		  	 United States of America
	  	13/001543	  	March 31, 2011
				
	25	  	Prostacyclin analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2007/026264	  	December 21, 2007
		  	 United States of America
	  	12/520493	  	December 21, 2007
		  	 United States of America
	  	12/489425	  	June 22, 2009
		  	 Japan
	  	2009-542961	  	December 21, 2007
		  	 Australia
	  	2007338701	  	December 21, 2007
		  	 Brazil
	  	PI0719463-3	  	December 21, 2007
		  	 Canada
	  	2672904	  	December 21, 2007
		  	 China (People’s Republic)
	  	2.0078E+11	  	December 21, 2007
		  	 Eurasian Patent Organization
	  	200900862	  	December 21, 2007
		  	 European Patent Convention
	  	7863238.7	  	December 21, 2007
		  	 India
	  	4730/DELNP/2009	  	December 21, 2007
		  	 Korea, Republic of
	  	10-2009-7015336	  	December 21, 2007
		  	 Mexico
	  	MX/a/2009/006692	  	December 21, 2007
		  	 South Africa
	  	2009/04722	  	December 21, 2007
				
	26	  	Prostacyclin analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/040891	  	July 2, 2010
				
	27	  	Pyrazinoisoquinoline compounds	  		  	
		  	 United States of America
	  	61/449312	  	March 4, 2011
				
	28	  	Pyrazinoisoquinoline compounds	  		  	
		  	 United States of America
	  	61/210279	  	March 17, 2009
		  	 United States of America
	  	13/256787	  	September 15, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2010/027476	  	March 16, 2010
		  	 African Union Territories (OAPI)
	  	NEW APPLICATION	  	September 15, 2011
		  	 Brazil
	  	NEW APPLICATION	  	September 19, 2011
		  	 European Patent Convention
	  	10709147.2	  	October 14, 2011
		  	 India
	  	7022/DELNP/2011	  	September 14, 2011
		  	 African Regional Industrial Property Organization
	  	 AP/P/2011/005932
	  	
				
	29	  	Pyridineamine derivatives	  		  	
		  	 United States of America
	  	13/120455	  	August 26, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/058212	  	September 24, 2009

  
 Page 4 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	30	  	Pyridineamine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/011417	  	October 2, 2008
		  	 Hong Kong
	  	11100851.5	  	October 2, 2008
		  	 Japan
	  	2010-527991	  	October 2, 2008
				
	31	  	Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/047557	  	September 1, 2010
				
	32	  	Substituted dioxopiperidinyl phthalimide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US11/064409	  	December 12, 2011
				
	33	  	Substituted dioxopiperidinyl phthalimide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US11/064238	  	December 9, 2011
				
	34	  	Substituted diphenylpyrazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/044704	  	August 6, 2010
				
	35	  	Substituted oxazolidinone derivatives	  		  	
		  	 United States of America
	  	12/228662	  	August 14, 2008
		  	 United States of America
	  	13/189003	  	July 22, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2008/009704	  	August 14, 2008
		  	 China (People’s Republic)
	  	200880107169.X	  	August 14, 2008
		  	 European Patent Convention
	  	8795304.8	  	August 14, 2008
		  	 Japan
	  	2010-521032	  	August 14, 2008
				
	36	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	12/380579	  	February 27, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/001305	  	February 27, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/001294	  	February 27, 2009
		  	 Argentina
	  	P090103281	  	August 26, 2009
		  	 Australia
	  	2009217680	  	February 27, 2009
		  	 Brazil
	  	PI0908107-0	  	February 27, 2009
		  	 Canada
	  	2716788	  	February 27, 2009
		  	 China (People’s Republic)
	  		  	February 27, 2009
		  	 Eurasian Patent Organization
	  	201001391	  	February 27, 2009
		  	 European Patent Convention
	  	9715566.7	  	February 27, 2009
		  	 Hong Kong
	  	11104595.8	  	May 9, 2011
		  	 India
	  	6533/DELNP/2010	  	February 27, 2009
		  	 Japan
	  	2010-548745	  	February 27, 2009
		  	 Korea, Republic of
	  	10-2010-7021407	  	February 27, 2009
		  	 Mexico
	  	MX/a/2010/009300	  	February 27, 2009
		  	 Pakistan
	  	787/2009	  	August 25, 2009
		  	 South Africa
	  	2010/06104	  	February 27, 2009
		  	 Taiwan
	  	98128631	  	August 26, 2009
		  	 Venezuela
	  	2009-001574	  	August 25, 2009

  
 Page 5 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	37	  	Pharmaceutically acceptable salt of a substituted oxo(or hydroxy)hexyl-1H-purine-2,6(3H,7H)-dione compound	  		  	
				
		  	 Pakistan
	  	390/2010	  	August 25, 2009
				
	38	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	12/874049	  	September 1, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/047574	  	September 1, 2010
				
	39	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	12/873991	  	September 1, 2010
		  	 United States of America
	  	12/874783	  	September 2, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/047708	  	September 2, 2010
				
	40	  	Substituted xanthine derivatives	  		  	
		  	 Hong Kong
	  	11104593	  	May 9, 2011
		  	 Philippines
	  	1-2010-501961	  	February 27, 2009
		  	 Japan
	  	2010-548747	  	February 27, 2009
		  	 European Patent Convention
	  	9714926.4	  	February 27, 2009
				
	41	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	61/509343	  	July 19, 2011
				
	42	  	Synthesis of deuterated catechols and benzo[D][1,3] dioxoles and derivatives thereof	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/010643	  	September 12, 2008
		  	 Australia
	  	2008299921	  	September 12, 2008
		  	 Canada
	  	2698808	  	September 12, 2008
		  	 China (People’s Republic)
	  	2.0088E+11	  	September 12, 2008
		  	 European Patent Convention
	  	8830527.1	  	September 12, 2008
		  	 Hong Kong
	  	10112245.6	  	December 30, 2010
		  	 India
	  	2015/DELNP/2010	  	September 12, 2008
		  	 Japan
	  	2010-524866	  	September 12, 2008
		  	 Mexico
	  	MX/a/2010/002692	  	September 12, 2008
		  	 United States of America
	  	12/283621	  	September 12, 2008
				
	43	  	Synthesis of deuterated morpholine derivatives	  		  	
		  	 United States of America
	  	12/456507	  	June 17, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/003628	  	June 17, 2009

  
 Page 6 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	44	  	Substituted dioxopiperidinyl phthalimide derivatives	  		  	
		  	 United States of America
	  	13/107873	  	May 13, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/045629	  	July 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/006105	  	November 13, 2009
		  	 Australia
	  	2009314568	  	May 17, 2011
		  	 Brazil
	  	PI0915267-9	  	May 12, 2011
		  	 Canada
	  	2743902	  	May 13, 2011
		  	 China (People’s Republic)
	  	2.0098E+11	  	November 13, 2009
		  	 Eurasian Patent Organization
	  	201100750	  	June 10, 2011
		  	 European Patent Convention
	  	9826438.5	  	June 9, 2011
		  	 India
	  	1038/MUMNP/2011	  	May 23, 2011
		  	 Japan
	  	2011-536328	  	May 13, 2011
		  	 Korea, Republic of
	  	10-2011-7013575	  	June 14, 2011
		  	 Mexico
	  	MX/a/2011/005112	  	May 13, 2011
		  	 Philippines
	  	1-2011-500901	  	November 13, 2009
		  	 South Africa
	  	2011/04361	  	June 10, 2011
				
	45	  	Azapeptide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/007331	  	June 12, 2008
		  	 European Patent Convention
	  	08252023.0	  	June 12, 2008
		  	 Argentina
	  	P080102501	  	June 12, 2008
		  	 Pakistan
	  	6842008	  	June 12, 2008
		  	 Taiwan
	  	97122018	  	June 12, 2008
		  	 Venezuela
	  	2008001156	  	June 12, 2008
		  	 Hong Kong
	  	09105433.5	  	June 17, 2009
		  	 European Patent Convention
	  	09075359.1	  	June 12, 2008
		  	 Australia
	  	2008267048	  	June 12, 2008
		  	 Brazil
	  	PI08139113	  	June 12, 2008
		  	 Canada
	  	2692028	  	June 12, 2008
		  	 China (People’s Republic)
	  	200880021601.3	  	June 12, 2008
		  	 Colombia
	  	09141805	  	June 12, 2008
		  	 India
	  	8182DELNP2009	  	June 12, 2008
		  	 Japan
	  	2010512186	  	June 12, 2008
		  	 Mexico
	  	MXa2009013565	  	June 12, 2008
		  	 South Africa
	  	200909079	  	June 12, 2008
		  	 Korea, Republic of
	  	1020107000675	  	June 12, 2008
		  	 Switzerland
	  	08252023.0	  	June 12, 2008
		  	 Germany
	  	08252023.0	  	June 12, 2008
		  	 Spain
	  	08252023.0	  	June 12, 2008
		  	 France
	  	08252023.0	  	June 12, 2008
		  	 United Kingdom
	  	08252023.0	  	June 12, 2008
		  	 Italy
	  	08252023.0	  	June 12, 2008
		  	 Hong Kong
	  	10104316.7	  	April 30, 2010
		  	 United States of America
	  	12/755,184	  	April 6, 2010
		  	 European Patent Convention
	  	11155667.6	  	June 12, 2008
		  	 Hong Kong
	  	11109198.8	  	August 31, 2011
		  	 China (People’s Republic)
	  	 2.0111E+11
	  	June 12, 2008
		  	 Brazil
	  	(divisional) instructions to file sent	  	

  
 Page 7 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	46	  	4-oxoquinoline derivatives	  		  	
		  	 United States of America
	  	12/283,620	  	September 12, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/010662	  	September 12, 2008
		  	 Australia
	  	2008299931	  	September 12, 2008
		  	 Canada
	  	2698825	  	September 12, 2008
		  	 European Patent Convention
	  	08830735.0	  	September 12, 2008
		  	 India
	  	2377DELNP2010	  	September 12, 2008
		  	 Mexico
	  	MXA2010002679	  	September 12, 2008
		  	 United States of America
	  	13/153,952	  	June 6, 2011
				
	47	  	Deuterated darunavir	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/012079	  	October 24, 2008
		  	 United States of America
	  	12/387,327	  	April 28, 2009
		  	 Australia
	  	2008317375	  	October 24, 2008
		  	 Canada
	  	2703591	  	October 24, 2008
		  	 European Patent Convention
	  	08843302.4	  	October 24, 2008
				
	48	  	Peptides for the treatment of HCV infections	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/012949	  	November 20, 2008
		  	 European Patent Convention
	  	08851195.1	  	November 20, 2008
		  	 Japan
	  	2010534960	  	November 20, 2008
		  	 Hong Kong
	  	11101960.1	  	February 28, 2011
				
	49	  	Endothelin receptor antagonists	  		  	
		  	 United States of America
	  	12/008,698	  	January 11, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/000384	  	January 11, 2008
		  	 United States of America
	  	12/460,575	  	July 20, 2009
				
	50	  	Selective endothelin type-A antagonists	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/001358	  	February 1, 2008
		  	 European Patent Convention
	  	8713376.5	  	February 1, 2008
				
	51	  	Deuterated piperazine derivatives as anti-anginal compounds	  		  	
		  	 United States of America
	  	12/075,107	  	March 7, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/003183	  	March 7, 2008
		  	 European Patent Convention
	  	08726679.7	  	March 7, 2008
		  	 Japan
	  	2009552765	  	March 7, 2008
		  	 Belgium
	  	08726679.7	  	March 7, 2008
		  	 France
	  	08726679.7	  	March 7, 2008
		  	 Germany
	  	08726679.7	  	March 7, 2008
		  	 United Kingdom
	  	08726679.7	  	March 7, 2008
		  	 Italy
	  	08726679.7	  	March 7, 2008
		  	 Spain
	  	08726679.7	  	March 7, 2008
		  	 Switzerland
	  	08726679.7	  	March 7, 2008

  
 Page 8 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	52	  	Tricyclic benzo[5,6]cyclonepta[1, 2- B]pyridine derivatives and uses thereof	  		  	
				
		  	 Patent Cooperation Treaty
	  	PCT/US2009/002372	  	April 16, 2009
		  	 United States of America
	  	12/937,933	  	April 16, 2009
				
	53	  	Piperazine derivatives	  		  	
		  	 United States of America
	  	12/386,492	  	April 17, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/002424	  	April 17, 2009
		  	 United States of America
	  	12/603,380	  	October 21, 2009
				
	54	  	Xanthenone-4-acetic acid derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2009/060996	  	October 16, 2009
		  	 United States of America
	  	13/124,626	  	October 16, 2009
				
	55	  	Hydroxyethlamino sulfonamide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2009/005773	  	October 23, 2009
		  	 United States of America
	  	13/125,464	  	October 23, 2009
		  	 European Patent Convention
	  	09822333.2	  	October 23, 2009
				
	56	  	Hydroxyethylamino sulfonamide derivatives	  		  	
		  	 United States of America
	  	12/771,551	  	April 30, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/033206	  	April 30, 2010
				
	57	  	Deuterium modified benzimidazoles	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/034962	  	May 14, 2010
		  	 United States of America
	  	13/320,653	  	November 15, 2011
				
	58	  	Peptides for the treatment of HCV infections	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/036682	  	May 28, 2010
		  	 United States of America
	  	13/321,785	  	November 21, 2011
				
	59	  	Aminoquinoline derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/021715	  	January 19, 2011
				
	60	  	Tetrahydroisoquinoline derivatives	  		  	
		  	 United States of America
	  	12/338,754	  	December 18, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/087477	  	December 18, 2008
		  	 European Patent Convention
	  	08862459.8	  	December 18, 2008
				
	61	  	Inhibitors of cholesterol ester transfer protein	  		  	
		  	 United States of America
	  	12/049,074	  	March 14, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/003449	  	March 14, 2008
		  	 Canada
	  	2681628	  	March 14, 2008
		  	 European Patent Convention
	  	08742105.3	  	March 14, 2008
		  	 Hong Kong
	  	10105723.1	  	June 9, 2010

  
 Page 9 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	62	  	Synthetic triterpenoid derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/049163	  	August 25, 2011
				
	63	  	Atazanavir metabolite derivatives	  		  	
		  	 United States of America
	  	61/495,877	  	June 10, 2011
				
	64	  	Atazanavir metabolite derivatives	  		  	
		  	 United States of America
	  	61/495,870	  	June 10, 2011
				
	65	  	Deuterated 18-methoxycoronadidine	  		  	
		  	 United States of America
	  	61/505,361	  	July 7, 2011
				
	66	  	Substituted diphenylpyrazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/044704	  	August 6, 2010
				
	67	  	Niacin prodrugs and deuterated versions thereof	  		  	
		  	 United States of America
	  	12/948,484	  	November 17, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/057051	  	November 17, 2010
				
	68	  	Pharmaceutical calcimimetics	  		  	
		  	 United States of America
	  	12/975,464	  	December 22, 2010
		  	 Canada
	  	2701638	  	April 1, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/059023	  	April 1, 2008
				
	69	  	1,2-benzisoxazol-3-yl compounds	  		  	
		  	 United States of America
	  	12/102,164	  	April 14, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/060210	  	April 14, 2008
				
	70	  	Naphthyl(ethyl)acetamides	  		  	
		  	 United States of America
	  	12/112,722	  	April 30, 2008
		  	 Canada
	  	2685924	  	April 30, 2008
		  	 European Patent Convention
	  	08769252.1	  	April 30, 2008
		  	 Japan
	  	2009-551067	  	April 30, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/062039	  	April 30, 2008
				
	71	  	Morphinan compounds	  		  	
		  	 United States of America
	  	12/112,936	  	April 30, 2008
		  	 United States of America
	  	13/118,912	  	May 31, 2011
		  	 United States of America
	  	13/118,935	  	May 31, 2011
		  	 Australia
	  	2008247818	  	April 30, 2008
		  	 Australia
	  	(divisional) instructions to file sent	  	
		  	 Brazil
	  	PI0811478-1	  	April 30, 2008
		  	 Canada
	  	2685723	  	April 30, 2008

  
 Page 10 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
		  	 China (People’s Republic)
	  	200880017768.2	  	April 30, 2008
		  	 European Patent Convention
	  	08747238.7	  	April 30, 2008
		  	 European Patent Convention
	  	11000763.0	  	April 30, 2008
		  	 European Patent Convention
	  	11000764.8	  	April 30, 2008
		  	 Hong Kong
	  	1010707.6	  	August 9, 2010
		  	 Hong Kong
	  	11109618.0	  	September 12, 2011
		  	 Hong Kong
	  	11109620.6	  	September 12, 2011
		  	 India
	  	7533/DELNP/2009	  	April 30, 2008
		  	 Japan
	  	2010-506617	  	April 30, 2008
		  	 Mexico
	  	2009/011958	  	April 30, 2008
		  	 Mexico
	  	MX/a/2011/010560	  	October 6, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2008/062089	  	April 30, 2008
				
	72	  	N-phenyl-2-pyrimidineamine derivatives	  		  	
		  	 United States of America
	  	12/539,091	  	August 11, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/053384	  	August 11, 2009
				
	73	  	Deuterated etravirine	  		  	
		  	 United States of America
	  	12/288,186	  	October 17, 2008
		  	 European Patent Convention
	  	08839230.3	  	October 17, 2008
		  	 Hong Kong
	  	11101126.2	  	October 17, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/011856	  	October 17, 2008
				
	74	  	Deuterated morpholinyl compounds	  		  	
		  	 United States of America
	  	12/106,127	  	April 18, 2008
		  	 Australia
	  	2008242703	  	April 18, 2008
		  	 Brazil
	  	P10810362-3	  	April 18, 2008
		  	 Canada
	  	2686545	  	April 18, 2008
		  	 China (People’s Republic)
	  	200880012551.2	  	April 18, 2008
		  	 European Patent Convention
	  	08746315.4	  	April 18, 2008
		  	 India
	  	7500/DELNP/2009	  	April 18, 2008
		  	 Japan
	  	2010-504289	  	April 18, 2008
		  	 Japan
	  	2011-18410	  	January 31, 2011
		  	 South Korea
	  	10-2009-7024119	  	April 18, 2008
		  	 South Korea
	  	10-2010-7020029	  	September 8, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2008/060877	  	April 18, 2008
				
	75	  	Deuterated 2-propylpentanoic acid compounds	  		  	
		  	 European Patent Convention
	  	09744570.4	  	October 28, 2009
		  	 United States of America
	  	13/126,384	  	April 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/062397	  	October 28, 2009
				
	76	  	Novel pyrimidinecarboxamide derivatives	  		  	
		  	 United States of America
	  	12/169,367	  	July 8, 2008
		  	 United States of America
	  	12/712,399	  	February 25, 2010
		  	 Canada
	  	2702317	  	July 8, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/069425	  	July 8, 2008

  
 Page 11 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	77	  	Deuterated tizanidine	  		  	
		  	 United States of America
	  	12/993,530	  	February 10, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/045245	  	May 27, 2009
				
	78	  	Analogs of d-dextromethorphan	  		  	
		  	 Australia
	  	2009293123	  	September 18, 2009
		  	 Brazil
	  	PI0918760-0	  	September 18, 2009
		  	 Canada
	  	2737811	  	September 18, 2009
		  	 China
	  	200980142670.4	  	September 18, 2009
		  	 Eurasia
	  	201170473	  	September 18, 2009
		  	 European Patent Convention
	  	09792714.9	  	September 18, 2009
		  	 European Patent Convention
	  	11188848.3	  	September 18, 2009
		  	 Hong Kong
	  	N/A	  	September 18, 2009
		  	 India
	  	2116/DELNP/2011	  	September 18, 2009
		  	 India
	  	(divisional) instructions to file sent	  	
		  	 Japan
	  	2011-527994	  	September 18, 2009
		  	 South Korea
	  	10-2011-7008130	  	September 18, 2009
		  	 South Korea
	  	10-2011-7027474	  	November 18, 2011
		  	 Mexico
	  	N/MX/a/2011/002994	  	September 18, 2009
		  	 Philipines
	  	1-2011-500574	  	September 18, 2009
		  	 United States of America
	  	13/119,905	  	July 1, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/057476	  	September 18, 2009
		  	 South Africa
	  	2011/02113	  	September 18, 2009
				
	79	  	Morphinan compounds	  		  	
		  	 United States of America
	  	13/155,827	  	June 8, 2011
				
	80	  	Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain
injury	  		  	
		  	 European Patent Convention
	  	09744582.9	  	October 30, 2009
		  	 European Patent Convention
	  	11180603.0	  	October 30, 2009
		  	 United States of America
	  	13/126,397	  	April 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/062783	  	October 30, 2009
				
	81	  	Methods for the treatment of neurological diseases and conditions	  		  	
		  	 European Patent Convention
	  	09744581.1	  	October 30, 2009
		  	 European Patent Convention
	  	11180608.9	  	October 30, 2009
		  	 United States of America
	  	13/126,447	  	April 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/062779	  	October 30, 2009

  
 Page 12 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	82	  	Substituted azaindoles	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/056447	  	November 12, 2010
				
	83	  	Pyrimidine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/025472	  	February 18, 2011
				
	84	  	Deuterated tetrahydronaphthalene derivatives	  		  	
		  	 United States of America
	  	13/038,533	  	March 2, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/026787	  	March 2, 2011
				
	85	  	Tetrahydronaphthalene derivatives	  		  	
		  	 United States of America
	  	13/227,047	  	September 7, 2011
				
	86	  	Novel pyrimidinecarboxamide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/043872	  	July 13, 2011
				
	87	  	Substituted azaindoles	  		  	
		  	 United States of America
	  	13/230,970	  	September 13, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/051297	  	September 13, 2011
				
	88	  	Substituted tetracyclines	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/060310	  	November 11, 2011
				
	89	  	Deuterated chlophedianol	  		  	
		  	 United States of America
	  	61/436,634	  	January 27, 2011
				
	90	  	2-amino-naphthyridine derivatives	  		  	
		  	 United States of America
	  	61/446,733	  	February 25, 2011
				
	91	  	Deuterated prelandenant	  		  	
		  	 United States of America
	  	61/466,310	  	March 22, 2011
				
	92	  	Deuterated N-butyl bumetanide	  		  	
		  	 United States of America
	  	61/484,412	  	May 10, 2011
				
	93	  	Synthetic triterpenoid derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	US11/34984	  	May 3, 2011
				
	94	  	[5,6]-dihydro-2H-pyran-2-one derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	US11/40731	  	June 16, 2011
				
	95	  	Derivatives of pyrazole-substituted amino-heteroaryl compounds	  		  	
		  	 United States of America
	  	61/448,887	  	March 3, 2011

  
 Page 13 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	96	  	Novel pharmaceutical compounds	  		  	
		  	 Australia
	  	2006275702	  	July 28, 2006
		  	 China (People’s Republic)
	  	200680036393.50	  	July 28, 2006
		  	 Japan
	  	2008-524206	  	July 28, 2006
		  	 United States of America
	  	11/704,555	  	February 8, 2007
		  	 United States of America
	  	12/954,591	  	November 24, 2010
		  	 European Patent Convention
	  	11155798.9	  	July 28, 2006
				
	97	  	Biphenyl-pyrazolecarboxamide compounds	  		  	
		  	 United States of America
	  	11/521,926	  	September 14, 2006
				
	98	  	Novel 1,2,3,4-tetrahydroquinoline derivatives	  		  	
		  	 United States of America
	  	12/296,927	  	September 30, 2009
				
	99	  	3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-YL)-4-propoxybenzenesulfonamide derivatives and methods of use	  		  	
		  	 Korea, Republic of
	  	10-2009-7010321	  	October 22, 2007
		  	 United States of America
	  	11/876,754	  	October 22, 2007
		  	 Japan
	  	2009-533595	  	October 22, 2007
		  	 India
	  	868/MUMNP/2009	  	October 22, 2007
		  	 Mexico
	  	MX/a/2009/003941	  	October 22, 2007
				
	100	  	Dibenzothiazepine derivatives	  		  	
		  	 United States of America
	  	12/425,957	  	April 17, 2009
				
	101	  	Triazolyl tropane derivatives	  		  	
		  	 United States of America
	  	11/941,925	  	November 16, 2007
		  	 United States of America
	  	13/044,534	  	March 9, 2011
				
	102	  	Heterocyclic kinase inhibitors	  		  	
		  	 European Patent Convention
	  	8859849.5	  	December 9, 2008
		  	 Hong Kong
	  	11102019	  	December 9, 2008
		  	 United States of America
	  	12/331,431	  	December 9, 2008
				
	103	  	Vandetanib derivatives	  		  	
		  	 United States of America
	  	12/864,219	  	November 16, 2010
				
	104	  	Derivatives of gefitinib	  		  	
		  	 European Patent Convention
	  	9703515.8	  	January 22, 2009
		  	 Hong Kong
	  	10111408.1	  	January 22, 2009
		  	 United States of America
	  	12/358,238	  	January 22, 2009
		  	 Japan
	  	2010-544356	  	January 22, 2009
		  	 United States of America
	  	12/946,856	  	November 15, 2010

  
 Page 14 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	105	  	Quinazoline derivatives and methods of treatment	  	11/957,442	  	December 15, 2007
		  	 United States of America
	  	12/694,249	  	January 26, 2010
				
	106	  	Derivatives of 3-(2-hydroxy-5-methyphenyl)-N,N-diisopropyl-3- phenylpropylamine and methods of use thereof	  		  	
		  	 China (People’s Republic)
	  	200980121626.50	  	April 9, 2009
		  	 Korea, Republic of
	  	10-2010-7025129	  	April 9, 2009
		  	 United States of America
	  	12/937,262	  	January 26, 2011
		  	 Japan
	  	2011-504185	  	April 9, 2009
				
	107	  	Substituted triazolo-pyridazine derivatives	  		  	
		  	 Canada
	  	2735549	  	August 28, 2009
		  	 European Patent Convention
	  	9810685.9	  	August 28, 2009
		  	 Eurasian Patent Organization
	  	201100409	  	August 28, 2009
		  	 Australia
	  	2009285533	  	August 28, 2009
		  	 Brazil
	  	PI0912928-6	  	August 28, 2009
		  	 China (People’s Republic)
	  	200980140350.50	  	August 28, 2009
		  	 Korea, Republic of
	  	10-2011-7006632	  	August 28, 2009
		  	 Philippines
	  	1-2011-500500	  	August 28, 2009
		  	 South Africa
	  	2011/02123	  	August 28, 2009
		  	 India
	  	438/MUMNP/2011	  	August 28, 2009
		  	 Japan
	  	2011-525250	  	August 28, 2009
		  	 Mexico
	  	MX/a/2011/002278	  	August 28, 2009
		  	 United States of America
	  	12/550,346	  	February 4, 2009
		  	 United States of America
	  	13/174,662	  	June 30, 2011
				
	108	  	3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-YL)-4-propoxybenzenesulfonamide derivatives and methods of use	  		  	
				
		  	 United States of America
	  	12/365,883	  	February 4, 2009
				
	109	  	Quinazoline derivatives and methods of treatment	  		  	
		  	 China (People’s Republic)
	  	200980118829.90	  	March 27, 2009
		  	 Korea, Republic of
	  	10-2010-7024204	  	March 27, 2009
		  	 Japan
	  	2011-502126	  	March 27, 2009
		  	 Hong Kong
	  	11108819.9	  	March 27, 2009
				
	110	  	4-aminoquinazoline prodrugs	  		  	
		  	 United States of America
	  	12/986,135	  	January 6, 2011

  
 Page 15 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	111	  	Deuterated macrocyclic inhibitors of viral NS3 protease	  		  	
		  	 United States of America
	  	13/092,801	  	April 22, 2011
				
	112	  	Substituted triazolophthalazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/045508	  	August 13, 2010
		  	 United States of America
	  	12/856,360	  	August 13, 2010
				
	113	  	Substituted benzimidazoles	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/052915	  	October 15, 2010
		  	 United States of America
	  	12/905,835	  	October 15, 2010
				
	114	  	Substituted imidazotriazines	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/043097	  	July 23, 2010
		  	 United States of America
	  	12/842,589	  	July 23, 2010
				
	115	  	Substituted triazolo-pyridazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/039497	  	June 22, 2010
		  	 United States of America
	  	12/820,570	  	June 22, 2010
				
	116	  	2-oxo-1-pyrrolidine derivatives	  		  	
		  	 United States of America
	  	13/002,267	  	June 30, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US09/49224	  	June 30, 2009
				
	117	  	Deuterated Tivozanib	  		  	
		  	 United States of America
	  	61/496,201	  	June 13, 2011
				
	118	  	Analogues of cilostazol	  		  	
		  	 United States of America
	  	12/150,107	  	April 24, 2008
		  	 United States of America
	  	12/644,758	  	December 22, 2009
		  	 EP
	  	8743256.3	  	November 25, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US08/05301	  	April 24, 2008
				
	119	  	4-aminoquinazolines	  		  	
		  	 Australia
	  	2007288204	  	August 22, 2007
		  	 Canada
	  	2,661,223	  	August 22, 2007
		  	 United States of America
	  	12/879,905	  	September 10, 2010
		  	 China (People’s Republic)
	  	200780093901.3	  	August 22, 2007
		  	 European Union
	  	EP07811504.5	  	August 22, 2007
		  	 India
	  	423/MUMNP/2009	  	August 22, 2007
		  	 Japan
	  	2009-525631	  	August 22, 2007
		  	 Mexico
	  	MX/a/2009/001814	  	August 22, 2007
		  	 United States of America
	  	11/895,174	  	August 22, 2007
		  	 Patent Cooperation Treaty
	  	PCT/US2007/018655	  	August 22, 2007
		  	 Korea
	  	2009-0042994	  	August 22, 2007

  
 Page 16 of 16

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	Argentina	  	CONCERT PHARMACEUTICALS INC.	  	2210582	  	01/29/2008	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/29/2018
						
	Australia	  	CONCERT PHARMACEUTICALS INC.	  	1157917	  	1/25/2007	  	A full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Australia	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	1157926	  	1/25/2007	  	A full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Canada	  	CONCERT PHARMACEUTICALS INC.	  	1,332,456	  	1/24/2007	  	A full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Pending
						
	Canada	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	1,332,461	  	1/24/2007	  	A full line of pharmaceutical and bio pharmaceutical preparations namely, pharmaceutical compounds for use in treating diseases and health conditions namely, pharmaceuticals for the
treatment of inflammatory diseases, infectious diseases, diseases and conditions of the central nervous system, cancer, and cardiovascular disease.	  	Pending
						
	China	  	CONCERT PHARMACEUTICALS INC.	  	5,868,162	  	3/7/2011	  	Medical nutriment	  	Registered, expires 3/6/2021
						
	China	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	5,868,163	  	3/7/2011	  	Medical nutriment	  	Registered, expires 3/6/2021

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	European Community	  	CONCERT PHARMACEUTICALS INC.	  	5641204	  	1/30/2008	  	 Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmaceutical and biopharmaceutical
preparations in Class 5.
  
 Pharmaceutical research and development services
in Class 42.
	  	Registered, expires 1/25/2017
						
	European Community	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	5641295	  	1/23/2008	  	Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmaceutical and biopharmaceutical preparations in Class 5.	  	Registered, expires 1/25/2017
						
		  		  		  		  	Pharmaceutical research and development services in Class 42.	  	
						
	India	  	CONCERT PHARMACEUTICALS INC.	  	1526295	  	1/25/2007	  	Full line of pharmaceutical and biopharmaceutical preparations	  	Pending
						
	Israel	  	CONCERT PHARMACEUTICALS INC.	  	197279	  	5/10/2009	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Japan	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	5060415	  	7/6/2007	  	Pharmaceuticals in Class 5	  	Registered, expires 7/6/2017
						
	Japan	  	CONCERT PHARMACEUTICALS INC.	  	5060416	  	7/6/2007	  	Pharmaceuticals in Class 5	  	Registered, expires 7/6/2017

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL

NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	New Zealand	  	CONCERT PHARMACEUTICALS INC.	  	762543	  	7/25/2006	  	Pharmaceutical and biopharmaceutical preparations but not including pharmaceutical preparations to treat hyperactivity and attention deficit disorder in children in Class
5	  	Registered, expires 7/25/2016
						
	Norway	  	CONCERT PHARMACEUTICALS INC.	  	239760	  	6/20/2007	  	Complete set of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 6/20/17
						
	Russian Federation	  	CONCERT PHARMACEUTICALS INC.	  	346050	  	3/20/2008	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Singapore	  	CONCERT PHARMACEUTICALS INC.	  	T07/017771	  	1/25/2007	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, Renewal due 1/25/2017
						
	South Africa	  	CONCERT PHARMACEUTICALS INC.	  	2007/01346	  	4/22/2010	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Switzerland	  	CONCERT PHARMACEUTICALS INC.	  	559007	  	6/1/2007	  	Pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Taiwan	  	CONCERT PHARMACEUTICALS	  	1297040	  	1/16/2008	  	Western medicine, biological medicine preparations in Class 5	  	Registered, Renewal due 1/15/2018
						
	United States	  	CONCERT PHARMACEUTICALS INC.	  	78937102	  	7/25/2006	  	Prescription pharmaceutical and biopharmaceutical preparations, namely, pharmaceutical preparations for use in treating inflammatory diseases, infectious diseases, cancer and
cardiovascular disease in Class 5	  	Published

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
		  		  		  		  	Pharmaceutical research and development services in Class 42	  	
						
	United States	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	78937142	  	7/25/2006	  	Prescription pharmaceutical and biopharmaceutical preparations, namely, pharmaceutical preparations for use in treating inflammatory diseases, infectious diseases, cancer and
cardiovascular disease in Class 5	  	Published
						
		  		  		  		  	Pharmaceutical research and development services in Class 42	  	

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	United States	  	DCE PLATFORM	  	77907107	  	1/7/2010	  	Pharmaceutical compounds for clinical study use in drug research, namely, deuterium-based compounds for research use; chemical compounds for making and studying pharmaceutical
compounds, namely, deuterium-based compounds wherein each chemical compound contains one or more deuterium atoms for use in the manufacture of pharmaceutical preparations; pharmaceutical compounds for clinical study for research purposes and
laboratory use in drug research, namely, deuterium-based compounds in Class 1	  	Allowed
						
		  		  		  		  	Pharmaceutical compounds for use in treating diseases and health conditions, namely, pharmaceuticals for the treatment of treatment of inflammatory and fibrotic diseases, infectious
diseases, diseases and conditions of the central nervous system, cancer, and cardiovascular and renal disease; pharmaceutical compounds for clinical study for therapeutic purposes, namely, deuterium-based compounds in Class 5	  	
						
		  		  		  		  	Scientific and medical research services; medical testing services for research purposes; conducting early evaluations in the field of new pharmaceuticals; drug discovery services;
pharmaceutical research services in Class 42	  	

 EXHIBIT E 
 BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS 
  

							
	 Bank Name
	  	 Account Number
	  	 Branch Address
	  	 Company/Subsidiary

				
	Silicon Valley Bank	  	3300530507	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub
				
	Silicon Valley Bank	  	3300580848	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub
				
	State Street Bank	  	DE3085	  	1200 Crown Colony Drive Quincy, MA 02169	  	Company x OR Name of Sub
				
	 State Street Bank
  

Note: All cash/investments moved to DE3085. Concert requested on 12/9/11 that the DE3086 be closed.
	  	DE3086	  	1200 Crown Colony Drive Quincy, MA 02169	  	 Company  ̈ OR
 Name of Sub Concert Pharmaceuticals Securities Corporation

				
	SVB Securities	  	486-04255	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub
				
	SVB Securities	  	486-05241	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub

 EXHIBIT F 
 COMPLIANCE CERTIFICATE 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Reference is made to that certain Loan and Security Agreement dated December     , 2011 and all
ancillary documents entered into in connection with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc.
(“Hercules”) as Lender and CONCERT PHARMACEUTICALS, INC. (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement. 

The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification
of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending
                     of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true
and correct in all material respects on and as of the date of this Compliance Certificate. Attached are the required documents supporting the above certification. The undersigned further certifies on behalf of the Company that these are prepared in
accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect
to revenue recognition for upfront and milestone payments, and are consistent from one period to the next except as explained below. 
  

					
	REPORTING REQUIREMENT	  	REQUIRED	  	 CHECK
 IF ATTACHED

			
	Interim Financial Statements	  	Monthly within 30 days	  	
			
	Interim Financial Statements	  	Quarterly within 45 days	  	
			
	Audited Financial Statements	  	FYE within 180 days	  	

  

			
	Very Truly Yours,
	
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Its:	 	  

 EXHIBIT G 
 FORM OF JOINDER AGREEMENT 
 This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of                          , 201  , and is entered into by and between
                    , a                     
corporation (“Subsidiary”), and Hercules Technology Growth Capital, Inc. as a Lender. 
 RECITALS 

A. Subsidiary’s Affiliate, CONCERT PHARMACEUTICALS, INC. (“Company”) has entered into that certain Loan and
Security Agreement dated December     , 2011, with Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith; 

B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the Loan
Agreement and the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Subsidiary and Lender agree as follows: 
  

	1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the
Loan Agreement. 

  

	2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the
Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and
delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties,
responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance with the Loan Agreement
or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an
Advance or make any other demand on Lender. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 [SIGNATURE PAGE TO JOINDER AGREEMENT] 

 

			
	SUBSIDIARY:
	
	  

		
	By:	 	  

	Name:	 	  

	Title:	 	  

		
	Address:	 	  

		
	Telephone:	 	  

	Facsimile:	 	  

  

							
	LENDER:	 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Its:	 	  

 EXHIBIT H 
 ACH DEBIT AUTHORIZATION AGREEMENT 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Re: Loan and Security Agreement dated December     , 2011 between CONCERT PHARMACEUTICALS, INC.
(“Borrower”) and Hercules Technology Growth Capital, Inc. (“Company”) (the “Agreement”) 
 In connection with the
above referenced Agreement, the Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account indicated below. The Borrower authorizes the depository institution
named below to debit to such account. 
  

			
	DEPOSITORY NAME	  	BRANCH
		
	CITY	  	STATE AND ZIP CODE
		
	TRANSIT/ABA NUMBER	  	ACCOUNT NUMBER

 This authority will remain in full force and effect so long as any amounts are due under the Agreement. 

 

			
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Date:	 	  

 SCHEDULE 1 
 SUBSIDIARIES 
 Concert Pharmaceuticals Securities Corp., a Massachusetts corporation

 SCHEDULE 1A 
 EXISTING PERMITTED INDEBTEDNESS 
 None. 

 SCHEDULE 1B 
 EXISTING PERMITTED INVESTMENTS 
 Investment in Concert Pharmaceuticals Securities Corp.

 SCHEDULE 1C 
 EXISTING PERMITTED LIENS 
 None. 

 SCHEDULE 5.3 
 CONSENTS, ETC. 
 None. 

 SCHEDULE 5.5 
 ACTIONS BEFORE GOVERNMENTAL AUTHORITIES 
 None. 

 SCHEDULE 5.8 
 TAX MATTERS 
 None. 

 SCHEDULE 5.9 
 INTELLECTUAL PROPERTY CLAIMS 
 None. 

 SCHEDULE 5.10 
 INTELLECTUAL PROPERTY 
 None. 

 SCHEDULE 5.11 
 BORROWER PRODUCTS 
 None. 

 SCHEDULE 5.14 
 CAPITALIZATION 
 Borrower owns all of the outstanding capital stock of Concert
Pharmaceuticals Securities Corp. See attached capitalization table of Borrower.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]